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Abstract 
 
Peloruside A, a natural product isolated from the marine sponge Mycale hentscheli, 
is a microtubule-stabilising agent that has a similar mechanism of action to the anti-
cancer drug paclitaxel and is cytotoxic to cultured mammalian cells. Peloruside 
appears to bind to a distinct site on mammalian tubulin that is different from that of 
the taxoid-site drugs. Because of the high sequence homology between yeast and 
mammalian tubulin, Saccharomyces cerevisiae (S. cerevisiae) was used as a model 
organism to characterise the peloruside-binding site with the aim of advancing our 
understanding about this site on mammalian tubulin. Wild type S. cerevisiae 
(BY4741) was sensitive to peloruside at µM concentrations; however, a strain that 
lacks the mad2 (Mitotic Arrest Deficient 2) gene showed increased sensitivity to the 
drug at much lower µM concentrations. This gene is a component of the spindle-
assembly checkpoint complex that delays the onset of anaphase in cells with defects 
in mitotic spindle assembly. The main aims of this project were to define the binding 
site of peloruside A using yeast tubulin to see if microtubule function and/or 
morphology is altered in yeast by peloruside, and to identify any secondary drug 
targets “friends of the target” through chemical genetic interactions profiling 
(Homozygous deletion profiling microarray).  
 
Site-directed mutagenesis was used to mutate two conserved amino acids (A296T; 
R306H) known to confer resistance to peloruside in mammalian cells. Based on a 
published computer model of the peloruside binding site on mammalian tubulin, we 
also mutated three other amino acids, two that were predicted to affect peloruside 
binding (Q291M and N337L), and one that was predicted to affect laulimalide 
binding but have little affect on peloruside binding (V333W). We also included a 
negative control that was predicted to have no effect on peloruside binding (R282Q) 
and would affect epothilone binding. We found that of the six point mutations, only 
Q291M failed to confer resistance in yeast and instead it increased the inhibition to 
the drug. Using a bud index assay, confocal microscopy, and flow cytometry, 40-50 
µM peloruside was shown to block cells in G2/M of the cell cycle, confirming a 
direct action of the drug on microtubule function.  
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Homozygous profiling (HOP) microarray analysis of a deletion mutant set of yeast 
genes was also carried out to identify gene products that interact with peloruside in 
order to link the drug to specific networks or biochemical pathways in the cells.  
 
From site-directed mutagenesis, we concluded that peloruside binds to yeast β-
tubulin in the region predicted by the published model of the binding site, and 
therefore mapping the site on yeast tubulin could provide useful information about 
the mammalian binding site for peloruside. The bud index, flow cytometry, and 
confocal microscopy experiments provided further evidence that peloruside interacts 
with yeast tubulin. From HOP we found that peloruside has roles in the cell cycle, as 
expected, and has effects on protein transport, secretion, cell wall synthesis, and 
steroid biosynthesis pathways. 
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Chapter 1. General introduction 
 
1.1. Background 
 
Yeast is a versatile and robust model system for studying eukaryotic cellular function. 
The adaptable genetic flexibility of yeast and the high degree of conservation 
between its cellular processes and those of human cells has made it a favoured model 
organism for new research in molecular and cell biology over the past four decades 
(Menacho-Márquez and Murguía, 2007). Technical advantages such as simple 
growth conditions, rapid cell division, and the simplicity of developing genetic tools 
for analysis of biological functions have encouraged the use of yeast as a screening 
tool in the field of drug discovery (Barberis et al. 2005). The yeast genome has 
approximately 6000 known genes (~1000 of these are essential). Approximately 73% 
(~4500 genes) of the genes are non-essential i.e. yeast missing any single non-
essential gene is still viable (Sherman, 1998). Over 29 human disease genes have 
been identified and cloned by functional complementation to their yeast homologues 
(Mushegian et al. 1997). Yeast is a valuable system for the detection of new drug 
targets, target-based and non-target-based drug screening, and full analysis of the 
cellular effects of drugs (Hughes, 2002). 
 
Currently, cancer is considered as one of the major health problems and is one of the 
major causes of death in the world. According to World Health Organisation (WHO), 
cancer caused approximately 7.4 million deaths (13% of all deaths worldwide) in 
2004 (WHO). It has been estimated that nearly 11 million people are diagnosed with 
cancer every year worldwide. Currently, there are more than 24.5 million people in 
the world living with cancer and probably 1 in 3 people will be diagnosed with 
cancer at some stage of their life. In 2005, statistics showed that 7.6 million people in 
the world died from cancer. Moreover, scientists predict that these  numbers will 
continue to rise, with 9 million people dying of cancer by the year 2015 and 11.4 
million dying in 2030 (WHO). In addition, New Zealand statistics showed that 
cancer is the second largest cause of death (with 27% of all deaths), second only to 
cardiovascular disease (www.stats.govt.nz). In the past decade, the pharmaceutical 
companies have been searching for a chemotherapeutic agent with novel properties 
to treat cancer. Current methods for treating cancer include surgery, radiotherapy and 
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chemotherapy. The vast majority of the chemotherapeutic drugs are cytotoxic agents 
that interfere with DNA replication and cell division (Workman, 2001). 
 
Microtubules are major dynamic structural components of the cytoskeleton. Yeast 
and other eukaryotic cells use microtubules in a variety of cell functions that are 
important for the development and maintenance of cell shape, cell reproduction and 
division (mitosis and meiosis), cell signalling, intracellular transport and cell 
movement (Anders and Botstein, 2001). Microtubules self-assemble from individual 
α/β-tubulin dimers (Fig. 1.1). Tubulin is one of the most abundant cellular proteins. 
Tubulin plays an important role in cell division, and with the fact that aberrant cell 
division is the hallmark of cancer, has made tubulin and microtubules prime targets 
for cancer chemotherapy. In fact, microtubule-targeting drugs like Taxol® 
(paclitaxel) are the most effective class of anticancer agents and are currently in 
clinical use (Zhou and Giannakakou, 2005). 
 
 
Figure. 1.1. Microtubule polymerisation. Tubulin heterodimers form a microtubule nucleus, 
followed by the assembly of 13 protofilaments that forms the microtubule. The plus end contains β-
tubulin at the outside and the minus end contains α-tubulin on the outside (Jordan and Wilson, 2004). 
 
The vast majority of microtubule-targeting agents (MTA) are natural products, but 
their chemical structures are remarkably diverse. These MTA are divided into two 
major groups (Jordan and Wilson, 2004): those that bind to the tubulin dimers and 
destabilise microtubules, such as the vinca alkaloids, cryptophycins, and colchicines, 
and those that bind to the microtubule polymer and stabilise microtubules, such as 
the taxanes (paclitaxel, docetaxel), epothilones, discodermolide, laulimalide, and 
peloruside. These MTA bind to different sites on the tubulin dimer and at different 
positions within the microtubule, and they have different effects on microtubule 
dynamics. However, they all block mitosis at the metaphase/anaphase transition, and 
because of mitotic block, they induce cell death. Paclitaxel showed excellent 
preclinical activities (Horwitz, 1992) and is now in general use for treatment of solid 
tumours of the breast, ovary, and lung (He et al. 2001; Stachel et al. 2001).  
- 5 - 
 
Laulimalide is a potent microtubule-stabilising agent (MSA) that was originally 
isolated from the sponge Cacospongia mycofijiensis (Mooberry et al. 1999). Similar 
to other MSA, laulimalide increases the number of interphase microtubules and 
induces microtubule bundles and abnormal mitotic spindles, effects that lead to 
mitotic arrest and initiation of cell death i.e. apoptosis (Pryor et al. 2002). 
Laulimalide binds to a unique site on tubulin relative to the taxoid site where most of 
the other microtubule stabilising agents bind. Peloruside A (PelA), a MSA from the 
marine sponge Mycale hentscheli (West et al. 2000), has a similar anti-mitotic effect 
to paclitaxel, laulimalide, and the other MSA. Competition for binding studies 
between peloruside, paclitaxel, and laulimalide revealed that peloruside and 
laulimalide competes with each other for binding, but not with paclitaxel, indicating 
that peloruside occupies the same or an overlapping site with laulimalide (Gaitanos 
et al. 2004).  
 
Determining the cellular function of a gene generally requires a method that can alter 
the gene’s product i.e. protein. Chemical genetics implies that a small bioactive 
molecule (drug) can bind to and alter the function of a gene, effectively creating a 
functional deletion mutant (synthetic lethal mutants or double mutants (refer to 
chapter 2 section 2.1.2)). Thus, the small molecule effect is similar to a mutation, and 
therefore the rules of genetics apply. Disrupting gene function is a valuable research 
tool in the field of genetics and helps in the understanding of gene function (Giaever 
et al. 2002). Chemical genetics is divided into two types: forward chemical genetics 
and reverse chemical genetics (Spring, 2004). Forward genetic screens are often used 
to characterise a mutated gene (phenotype to genotype); whereas, reverse genetics 
starts with a mutated gene in order to find a phenotype (genotype to phenotype). 
Chemical genetic screens can use either forward or reverse genetic approaches. One 
major advantage of using yeast as a model organism in chemical genetics is that a 
complete set of gene deletion mutant strains (96% of yeast open reading frames 
(ORF)) is available for screening (Winzeler et al. 1999). Yeast knockout studies have 
been used successfully for many years as a model organism for studying the 
pathways involved in mammalian diseases (Hartwell, 2002). The deletion mutants 
were created by homologous recombination in which each gene was deleted from 
start to stop codon and replaced with a kanamycin resistance cassette (Giaever et al. 
2002). Chemical genetic interaction techniques such as microarray apply the rules of 
chemical genetics to uncover synthetic lethal interactions of a drug. A microarray is a 
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collection of DNA spots that generally each represent a single gene. The DNA spots 
are directly synthesised or covalently attached to chemically suitable matrix or solid 
surface (Marchionni et al. 2008). The technique is particularly efficient and useful to 
study drugs that are in limited supply as it allows the whole experiment to be carried 
out in a small liquid volume (Pan et al. 2004). 
 
Understanding the biological targets and the mode of action of new compounds is 
essential for the process of developing new therapeutic compounds, and this 
understanding enhances the development of even more effective second-generation 
compounds.  
 
1.2. Microtubule stabilising agents (MSA) 
Tubulin interacts with a wide array of natural products, and as mentioned before, 
these compounds all differ in terms of their species of origin, molecular structure, 
and mechanism of interaction with the target. In the last decade, the number of 
distinct antimicrotubule compounds isolated from natural sources has more than 
doubled, and many of these compounds have been extraordinarily cytotoxic. They 
are of great interest as potential agents for the treatment of human diseases, 
particularly cancer (Wilson and Jordan, 2004), and they provide new tools for the 
study of the roles of microtubules in cell biology. 
 
MSA promote tubulin polymerisation into microtubules and block microtubule 
dynamics, leading to abnormal mitosis and subsequent apoptosis (Jordan, 2002). 
Paclitaxel, the first MSA discovered (Schiff et al. 1979), promotes the in vitro 
assembly of mammalian tubulin in the absence of GTP, a co-factor that is normally 
required for microtubule assembly, and the microtubules formed are stable against 
conditions normally favouring depolymerisation, such as cold temperatures, high 
Ca2+, and dilute solutions (Schiff et al. 1979). Paclitaxel induces microtubule 
stabilisation in vivo and causes formation of characteristic microtubule bundles in the 
cytoplasm of interphase cells (Schiff and Horwitz, 1980). The clinical successes of 
paclitaxel (Taxol®) and docetaxel (Taxotere®) have triggered a search for new agents 
with similar mechanisms of action but without the disadvantages of paclitaxel (refer 
to section 1.4) and docetaxel (Buey et al. 2005). Screenings of natural products from 
various sources like corals, marine sponges, and bacteria have led to the discovery of 
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huge number of structurally unrelated drugs that stabilise microtubules and mimic 
the activity of paclitaxel/docetaxel (Wang et al. 2002; Buey et al. 2005). The MSA 
drugs are usually classified into three groups with respect to their binding site on 
tubulin (Buey et al. 2005). The first group includes those that bind to the paclitaxel 
site in microtubules. This group comprises paclitaxel (taxoid), docetaxel (He et al. 
2001), the epothilones (Bollag el al. 1995) and discodermolide (Ter Haar et al. 1996). 
The second group of compounds includes the two that bind to the laulimalide binding 
site. This group comprises two compounds, laulimalide (Pryor et al. 2002) and 
peloruside A (Hood et al. 2002). The third group includes compounds that have, 
actually or potentially, microtubule-stabilising activity but whose binding to 
microtubules has not been described. This group includes the plant steroids 
taccalonolides A and E (Tinley et al. 2003) and the marine sponge compound 
zampanolide (Field et al. 2009). 
 
Laulimalide and peloruside are effective in paclitaxel-resistant cells that carry β-
tubulin gene mutations that modify the taxoid binding site (Pryor et al. 2002; 
Gaitanos et al. 2004). MSA can also be classified into three groups based on their 
chemical structure: i) the terpenoids (taxanes), ii) the macrolides (epothilone, 
laulimalide, peloruside, and zampanolide), and iii) the polyhydroxylated alkatetraene 
lactones (discodermolide) (Gaitanos et al. 2004). Both peloruside and the epothilones 
have a 16-membered ring structure; whereas, laulimalide and zampanolide have a 
20-membered ring structure. 
 
Although paclitaxel and the other MSA promote tubulin assembly in mammalian 
cells (Schiff et al. 1979), paclitaxel has no effect on isolated yeast tubulin (Bode et 
al. 2002). Epothilone on the other hand, stabilises yeast microtubules in vitro, but it 
is relatively ineffective in inhibiting yeast growth in vivo. Gupta et al. (2003) showed 
that the differences in the mode of action of paclitaxel on yeast tubulin and 
mammalian tubulin lay in five key amino acids that differed between the two types 
of tubulin. By changing these amino acids in yeast to those found in bovine brain 
tubulin, paclitaxel was able to polymerise purified yeast tubulin in a similar manner 
to mammalian tubulin (Gupta et al. 2003).  
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1.3. Mechanism of action for microtubule-targeting drugs  
The main effect of microtubule-targeting drug is to block the cell cycle in mitosis at 
the G2/M phase (Fig. 1.2).  
 
 
Figure. 1.2. Mammalian (left) and Yeast (right) cell cycle. The cell cycle is divided into interphase 
and mitosis. In interphase the genetic material of the cell is doubled; in the case of yeast it is the bud 
emergence state. In mitosis, the genetic component of the cell is divided equally between two 
daughter cells; in the case of the yeast between the mother and daughter cell. Most MSA arrest the 
cells at the G2/M phase of cell division (mammalian cell cycle figure adopted from Wan Laboratory 
website, 2003; yeast cell cycle figure adopted from Herskowitz, 1988). Note that cycle diagrams are 
not representative of the actual time spent in each phase.  
 
Currently, there are four known drug-binding sites on tubulin: three that are well 
characterised and a fourth that is not yet fully established. The names of the binding 
sites have been assigned according to the drug that was originally found to bind that 
specific site. The taxane binding site on β-tubulin is shared by most drugs that 
stabilise microtubules and bind preferentially to the microtubule polymer (Fig. 1.3) 
(Rao et al. 1992; Löwe et al. 2001).  
                                  
  
Figure. 1.3. Three-dimensional model of α/β-tubulin heterodimer. The Taxol-binding site on β-
tubulin is close to the M-loop (red). Figure on the right shows the key amino acids that are involved in 
the paclitaxel-binding site on β-tubulin (Orr et al. 2003; Synder et al. 2001). 
 
An example of a drug that binds to this site is paclitaxel (Fig. 1.4) (Eisenhauer and 
Vermorken, 1998), but other members of the microtubule-stabilising group bind as 
 
MSA 
MSA 
 
well, including the epothilones (Bollag 
1996), eleutherobin and the sarcodictyins (Long 
Figure. 1.4. Chemical structure of drugs that bind to the taxane binding site on 
paclitaxel, (b) epothilone A and B , and 
2001). 
 
The two other well-characterised binding sites on tubulin are shared by drugs that 
bind preferentially to unpolymerised tubulin and thus inhibit tubulin assembly, the 
colchicine site (Taylor, 
binding site on tubulin has only recently been discovered. This new site belongs to 
the MSA laulimalide (Pryor 
1.5). Laulimalide was th
taxane site on the microtubule polymer. 
Figure. 1.5. Chemical structre of laulimalide and peloruside A
other than the taxane site, on the microtubule poly
 
Since laulimalide and peloruside can compete with each
paclitaxel, for binding (Gaitanos 
peloruside are probably identical or at least ov
involved in this fourth binding site appear to be 
however, the evidence is based on computer modelling of drug
Other modelling studies have suggested that the site is on 
al. 2004; Jimenez-Barbero 
studies and deuterium
(a) 
et al. 1995), discodermolide (Ter Haar 
et al. 1998).  
 
 
(c) discodermolide (Zhou and Giannakakou, 2005; He 
1965) and the vinca alkaloid site (Bai et al. 
et al. 2002) and peloruside A (Gaitanos 
e first MSA discovered that bound to a 
 
 
. Both drugs bind to 
mer (Pryor et al. 2002; Gaitanos
 other, but not with 
et al. 2004), the binding sites of laulimalide and 
erlapping. The tubulin isotype 
β-tubulin (Huzil 
-tubulin interactions. 
α- not β
et al. 2006). Huzil et al. (2008) using computer docking 
-hydrogen exchange mass spectrometry (HDX
(+) Discodermolide 
(c) 
laulimalide 
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et al. 
 
β-tubulin. (a) 
et al. 
1990). A fourth 
et al. 2004) (Fig. 
site other than the 
 
a binding site, 
 et al. 2004). 
et al. 2008); 
-tubulin (Pineda et 
-MS) proposed 
(b) 
peloruside A 
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the peloruside binding site to be on β-tubulin. There is still uncertainty as to which 
binding site is correct, and the sorting out of this controversy is one of the aims of 
this thesis. 
 
1.4. Peloruside A 
Peloruside A (peloruside), a polyoxygenated metabolite with a 16-membered 
macrolactone,  was isolated by West, Northcote and Battershill in 1999 (West et al. 
2000) from the marine sponge Mycale hentschelli collected in Pelorus Sound on the 
north coast of the South Island of New Zealand. Sponges of the Mycale genus 
(Figure 1.6a) are a rich source of bioactive secondary metabolites. In addition to 
peloruside, M. hentschelli had already yielded protein synthesis inhibitor mycalamide 
A and B and the immunosuppressant pateamine (Figure 1.6b &c), both antineoplastic 
cytotoxins that had previously been isolated from specimens of the sponge found at 
other locations than Pelorus Sound (Page et al. 2005a, b). 
 
 
Figure. 1.6. (a) Sea sponge Mycale hentscheli. Mycale sponges grow in Pelorus Sound, Marlborough 
and produce the natural compound called peloruside A, pateamine and mycalamide (figure from 
biotechlearn.org). (b) The structures of pateamine and (c) The structures of mycalamide A (Northcote 
et al. 1991; Perry et al. 1988). 
 
Key structural features of peloruside are found in the 16-membered macrolactone 
that has its origins in polyketide biosynthesis (Williams et al. 2008). Initial studies 
have shown that peloruside induces apoptosis in transformed and untransformed cells 
in a dose-dependent manner (Miller el al. 2004). The action of peloruside on its 
primary target tubulin is remarkably similar to that of paclitaxel in cell lines and with 
purified tubulin (Hood et al. 2002); however, it does not activate either caspase-8 or 
(b) (a) 
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caspase-9 to any significant extent in HL60 cells (Miller el al. 2004). After two-day 
exposures to either peloruside or paclitaxel at 100 nM concentration, human lung 
adenocarcinoma H441 cells showed multiple micronuclei that increased upon longer 
exposures. Microtubule fibre bundles and multiple asters (the centres of the ends of 
the spindle formed during metaphase), were observed to form, observations 
consistent with those seen for other MSA, including discodermolide and the 
epothilones (Miller el al. 2004; Williams et al. 2008). 
 
The unique structure and properties of peloruside may convey benefits over the 
widely used chemotherapeutic agent paclitaxel. Paclitaxel is lipophilic, having low 
aqueous solubility, and therefore is administered to the patient dissolved in 
polyoxyethylated castor oil (Cremophor EL). This substance contributes to 
paclitaxel’s undesirable side effects, including hypersensitivity reactions. Moreover, 
paclitaxel’s hydrophobicity contributes to the development of multiple-drug 
resistance (MDR), a phenotype that tumour cells can develop which results in the 
efflux of a broad range of organic compounds (including paclitaxel) from the cell. 
This phenotype has generally been associated with over-expression of the P-
glycoprotein (Pgp) efflux pump (Horwitz, 1992). Peloruside is considerably less 
lipophilic than paclitaxel, suggesting that it should be both easier to administer, and 
active in MDR cell lines who also acquired a mutation in the paclitaxel binding site 
on β-tubulin (Giannakakou et al. 1997; Hood et al. 2002). Indeed, it has been shown 
that peloruside is less susceptible than paclitaxel to MDR arising from 
overexpression of the Pgp pump (Gaitanos et al. 2004). Peloruside cytotoxic action 
was furthermore not affected in cell lines with mutations that alter the taxoid binding 
site on β-tubulin (Gaitanos et al. 2004). These observations are similar to those 
reported for laulimalide, which had been shown to bind to a different site to 
paclitaxel (Mooberry et al. 1999; Pryor et al. 2002). The binding properties of 
peloruside (and laulimalide) are therefore distinctly different from other microtubule 
stabilising agents such as paclitaxel, the epothilones and discodermolide. 
Importantly, this suggests that they may be very useful chemotherapeutic agents 
against tumour cells that have developed the MDR phenotype. Peloruside 
cytotoxicity is comparable to other MSA, with IC50 values ranging from 4 nM to 15 
nM in different mammalian cell lines. To date, all peloruside research has been done 
with mammalian cell line. Along with the study by Wilmes (PhD thesis, 2008), this 
is  is the first study that utilises budding yeast as a model organism to apply the 
principle of chemical genetics. 
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1.5. Research design  
Extensive research has been directed towards understanding the tubulin-peloruside 
interaction. The aim of this project is to study the mode of action of peloruside on 
yeast microtubules and to identify tubulin key amino acid residues involved in 
peloruside binding. Yeast and human brain tubulin share about 75% sequence 
homology (Fig. 1.7) (Barnes et al. 1992). 
 
Homologous recombination occurs more frequently in yeast than in higher 
eukaryotes (Symington, 2002); hence, homologous recombination been considered 
as one of the most important tools in yeast genetics (Court et al. 2002). Therefore, 
yeast can be used to make knockout and/or mutant strains by using PCR to replace a 
yeast entire gene in through designed oligonucleotides that share sequence 
homologies with a deletion cassette or to create point mutations into the gene of 
interest. Peloruside-resistant yeast cells can be generated by site-directed 
mutagenesis based on the key amino acids in the peloruside binding site on tubulin 
(using PCR). These mutations may prevent peloruside from binding to tubulin and 
with high affinity and may interfere with normal microtubule dynamics. For 
example, paclitaxel-resistant mammalian cell lines, in some cases, contain 
‘hypostable’ microtubules in which the equilibrium between the dimer and polymer 
is shifted towards the former, making the cells drug-dependent. The stability of the 
polymer is apparently perturbed to such an extent that normal cell function is 
compromised, and the cells require low concentrations of paclitaxel for survival 
(Derry et al. 1995). Since low concentrations of MSA can inhibit microtubule 
dynamics without altering polymer mass, this drug-dependence phenomenon is not 
so surprising (Derry et al. 1995; Wilson and Jordan, 1995; Jordan and Wilson, 1998; 
Goncalves et al. 2001).  
 
Huzil et al. (2008) used a combination of HDX-MS data and local docking 
simulations to reveal individual peptides that could be directly involved in the 
binding pocket of the drug on tubulin. These peptides, as shown in Fig. 1.8, are 
β294-301 (H9-H9′loop), β302-314 (H9′-S8), and β332-340(H10-loop).  
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Figure. 1.8. Proposed peloruside binding site on β-tubulin as determined by a combination of 
labelling data and local docking simulations. Individual peptides detected by HDX-MS are 
indicated in colour: green: H9-H9′loop; brown: H9′-S8; cyan: H10-loop.  Helix H9 is in gray (β286-
293). Select side-chains suggested to be significant in defining the binding pocket are labelled. 
Oxygens of peloruside are coloured in red (Huzil et al. 2008). 
 
 
Wilmes (PhD thesis, 2008) noted that a single point mutation that changed amino 
acid 296 from alanine to threonine led to increased resistance in the PelA-R1 cells 
and PelA-R2 cells, giving a 5-fold resistance to peloruside compared to the parental 
1A9 cells. Giannakakou from the Weill Medical College of Cornell University 
(unpublished data) found a single amino acid mutation R306H/C in a 1A9-L4 cell 
line increased resistance to laulimalide by 40-fold. Generating a single amino acid 
change in yeast is relatively much easier to do via PCR because of its genome 
simplicity and the high incidence of homologous recombination in yeast.  
 
Chemical genetic interactions profiling (like homozygous and heterozygous 
microarray profiling) usually follow a three-step procedure: i) deletion mutant strains 
of yeast are grown, ii) a high-throughput screen for ligands (drugs) that affect the 
biological process of interest is carried out (usually growth), and iii) protein targets 
of the active ligands are identified (Stockwell, 2000). Both heterozygous profiling 
(HIP) and homozygous profiling (HOP) rely on microarray DNA analysis, which 
uses the same three steps. The use of heterozygotes, as well as the homozygous, has 
proven to be particularly powerful for drug target identification in in vitro and in vivo 
studies. Yeast genetic screens for resistant cell lines can be carried out either by 
transferring the mutagenised yeast strains from control medium to drug-containing 
medium by replica plating, or antibiotics-containing medium can also be used such 
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as NatMX or G418 when the drug is in limited supply. Drug-resistant colonies (or 
antibiotics-resistant) would grow, in the drug-treated medium compared to the 
control medium. Alternatively, if the drug of interest is in limited supply, as 
mentioned before, an oligonucleotide (primers) could be designed to carry the 
desired amino acid point mutation to insert into the yeast genome via transformation. 
Ultimately, via colony PCR (where DNA genomic purification is unnecessary), and 
with the aid of the designed synthetic oligonucleotide (primers), a single colony that 
has the desired point mutation could be selected at random. This precious colony 
then would be subjected to the drug to test its hypersensitivity or resistance level. 
From cell division to cancer, yeast has helped researchers to grasp biological 
principles and the work of this thesis continues that tradition. 
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1.6. Aims of this research  
The aims of this thesis are: 
1.6.1. Identify peloruside binding site on yeast tubulin 
The peloruside binding site will be determined by site-directed mutagenesis of S. 
cerevisiae yeast tubulin. This approach will map the amino acid positions that play 
an important role in the binding of peloruside to yeast tubulin. Site-directed 
mutagenesis will be used to mutate β-tubulin specific amino acids (A296T; R306H) 
that have been previously identified in resistant mammalian cell lines. Both 
mutations (individually) confer resistance to peloruside in mammalian cells (Wilmes 
PhD thesis, 2008). Besides those two mutations, and based on a published computer 
model of the peloruside binding site on mammalian tubulin, three other amino acids 
will also be modified to test their predicted effect on peloruside binding to β-tubulin. 
Two out of the three amino acids are predicted to affect peloruside binding (Q291M 
and N337L), one is predicted to affect laulimalide binding but have little affect on 
peloruside binding (V333W). In addition, one amino acid is included as a negative 
control that is predicted to have no effect on peloruside (R282Q). This information 
will help advance our understanding, by extension, of the mammalian peloruside 
binding site on tubulin.  
 
1.6.2. Determining peloruside target 
Provide evidence that peloruside is targeting the microtubules in yeast by a) 
validating the effect of mutation sites on yeast tubulin; that confer resistance to 
known mammalian peloruside binding site; b) looking for microtubule 
morphological effects using confocal microscopy; c) examining cell cycle block in 
yeast by peloruside, using budding index and flow cytometry. 
 
1.6.3. Investigate effects of point mutation using other MSA  
Testing the colonies that are resistant to peloruside, with other MSA to determine the 
effects of the point mutation on peloruside binding site on tubulin, and to look at the 
differences in the binding interaction between different MSA. 
 
1.6.4. Identify any secondary drug targets of peloruside HOP 
microarrays.  
The HOP was used to identify secondary targets. This assay will yield valuable 
information to identify genes that are required for cell survival or buffer the cell 
response in the presence of peloruside. 
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Chapter 2. Peloruside binding site on yeast tubulin: Site-directed 
mutagenesis 
 
2.1. Introduction 
2.1.1. Introduction to yeast properties  
 
Yeast cells are robust, fast growing (one generation every 90 min under normal 
laboratory conditions) and can be easily manipulated in 96- or 384-multiwell 
formats. Yeast cultures do not require sterile techniques or complex media and can 
be stored in standard refrigerators. Furthermore, there is a wide range of strains, 
vectors and genetic tools that allow researchers to quickly develop yeast-based 
bioassays (Birrell et al. 2001). This range of techniques facilitates the analysis of 
complex pathways in yeast that is difficult in more complex organisms. A significant 
advantage of budding yeast is the ability to incorporate DNA fragments into the 
genome by homologous recombination. This allows the precise insertion of DNA 
sequences at specific locations in the yeast genome (Menacho-Márquez and 
Murguía, 2007).  
 
The budding yeast is a valuable system to study cell cycle regulation. The cell cycle 
machinery is highly conserved between yeast and humans; hence, yeast studies are 
directly relevant to anticancer drug discovery since cell cycle dysregulation is a 
hallmark of cancer. Besides, studies in yeast have greatly contributed to our 
understanding of the drug biological targets and its modes of action. Understanding 
the mode of action of clinically relevant compounds is essential for the design of 
improved second-generation molecules (Qaddouri et al. 2009). 
 
2.1.2. Introduction to chemical genetics 
 
Synthetic lethality and synthetic sickness (collectively known as SSL) are genetic 
interactions in which two separate strains with a single mutation are viable but result 
in reduced or no growth when those mutations are combined in a double mutant. SSL 
was the concept behind the development of Synthetic Genetic Array analysis (SGA). 
SGA is a high-throughput technique for exploring synthetic lethal and synthetic sick 
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genetic interactions (SSL) that was initially developed by Tong et al. in 2001. 
Genetic enhancement is a phenomenon in which a mutant phenotype is altered to 
enhance growth by the addition of a second mutation that rescues the deleterious 
effect of the first mutation. The synthetic lethality (SL) technique is able to reveal 
“friends” of the target gene, that is, genes that are required to buffer cellular 
responses against the cytotoxic effects of a compound when the compound’s target 
function has been knocked out or knocked down. 
 
Chemical synthetic lethality (CSL) is a concept that aids in the characterisation of a 
novel compound’s bioactivity. In CSL, a compound acts as a ‘second mutation’ that 
alters the activity of a specific protein of the corresponding gene. Mutants 
hypersensitive to a drug represent CSL interactions and point directly to the drug 
target (Fig. 2.1.1). 
      
 
Figure. 2.1.1. Chemical synthetic lethality (CSL) versus synthetic lethality (SL). In CSL, a drug 
(or compound) acts as the second mutation (figure adopted from Boone et al. 2007).  
 
2.1.3. Peloruside A properties and applications 
 
Peloruside A (PelA), is a potent antitumor macrolide that shares a molecular target 
with Taxol®, a cancer therapy agent that is been developed for use against ovarian 
and breast cancer. Taxol® gross sales were more than $US2 billion a year, but the 
pharmaceutical industry is looking for a replacement with similar mechanisms of 
action but improved properties. Peloruside is one of the compounds that is being 
assessed as a second generation Taxol®-like anti-cancer agent. PelA is under 
development as an anti-cancer drug by REATA Pharmaceuticals Inc., a Dallas-based 
biopharmaceutical company in Texas, USA and REATA are hoping to start clinical 
trials soon. 
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The chemical properties of PelA (Fig. 2.1.2) show that this drug has five donor 
hydrogen bonds (a hydrogen atom attached to a relatively electronegative atom like 
oxygen is a hydrogen bond donor), and eleven hydrogen acceptor bonds (an 
electronegative atom such as oxygen or nitrogen is a hydrogen bond acceptor). 
Hydrogen bonds form important interaction points with the targeted protein in the 
binding site region. In one study that used a combination of hydrogen-deuterium 
exchange mass spectrometry (HDX-MS) labelling data and local docking 
simulations, it was proposed that PelA binds to the H1-S2 loop and the M loop of β-
tubulin (Huzil el al. 2008). The binding was localised (as mentioned in Chapter 1 
section 1.5) to the exterior surface of β-tubulin, at peptides β294-301, β302-314, and 
β332-340 (Huzil el al. 2008). However, other modelling studies have suggested that 
the site is on α- not β-tubulin (Pineda et al. 2004; Jimenez-Barbero et al. 2006). 
Taking advantage of yeast homologous recombination and using site-directed 
mutagenesis, one or more of these amino acids (shown in Fig. 2.1.2) and (Table. 
2.1.1) can be tested to confirm the importance of these binding interactions and 
further validate the direct involvement of these specific amino acids in the binding 
interactions with PelA. 
 
Figure. 2.1.2. 2D-schematic view of β-tubulin-peloruside interactions. Interactions are based on 
computer docking modelling. Q229, N337 and Q291 are H-donors; whereas, R306 is an H-acceptor. 
The choice of amino acid residues for β-tubulin mutagenesis was adopted from computer modelling 
studies carried out by Prof Jim Snyder and Dr Pahk Thepchatri at Emory University, Chemical 
Biological Discovery Centre, Department of Chemistry, Atlanta, Georgia, USA (unpublished data).  
 
Table. 2.1.1. Predicted PelA-sensitive sites on β-tubulin.  
 
Functional Group 
 
Residues 
 
Importance 
 
Predicted effect 
7 OMe R306 Direct interaction with R306 Resistance to PelA 
2 OH N337 H-bond Resistance to PelA 
13 OMe Q291 H-bond Resistance to PelA 
16 Me V333 weak hydrophobic bond 
Resistance to laulimalide 
but have less of an effect 
to PelA 
 
This table shows likely sites on β-tubulin that should be involved with PelA binding, based on 
the computer modelling data of Snyder and Thepchatri at Emory University, Chemical 
Biological Discovery Centre, Department of Chemistry, Atlanta, Georgia, USA (unpublished 
data).  
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Besides these point mutations listed above that should interfere with PelA binding to 
yeast tubulin, a negative control is also required to determine the non-specific effect 
of inducing a single point mutation in yeast tubulin, since this amino acid is not 
located in the proposed binding site. Previous studies done by Giannakakou et al. 
(1997; 2000) have developed β-tubulin mutations in amino acid β282 in the 1A9 
human ovarian carcinoma cell line (B10 cell line) that have resulted in resistance to 
epothilone A and B (EpoA and B). In our laboratory, a PelA-resistant cell line (PelA-
R1 cells) was generated in 1A9 cells by exposing the parental cells to gradually 
increasing concentrations of drug in the presence of verapamil, a drug that blocks the 
P-glycoprotein (Pgp) drug efflux pump.  
 
Using this method it should have been possible to generate resistant cells that carry a 
mutation in either α-tubulin or β-tubulin. However, the amino acid change in PelA-
R1 cells was at position 296 in β-tubulin that changed alanine to threonine and 
resulted in 5-fold resistance to PelA compared to the parental 1A9 cells (Wilmes 
PhD thesis, 2008). In addition, in another study with 1A9 cells by Dr Paraskevi 
Giannakkaou (unpublished data), mutations at amino acid R306 in β-tubulin gave 
66% R306H expression and 33% R306C expression in the mutant cells. This 1A9-L4 
cell line was found to be approximately 40-fold resistance to laulimalide, a 
microtubule-stabilising drug that binds to a similar site on tubulin to PelA (Gaitanos 
et al. 2004). The site of such a mutation would provide valuable information about 
the possible interaction of PelA and laulimalide with the microtubule and whether 
the α- or β-monomer was involved. Thus, identification of two independently derived 
cell lines resistant to PelA following mutations in the Huzil et al. (2008) location on 
β-tubulin provides good evidence that the PelA binding site is on β-, not α-tubulin. 
Using this information together with computer docking approaches could help 
decipher the PelA binding site on tubulin and determine whether PelA and 
laulimalide bind to the same or an overlapping site on the tubulin molecule. 
 
2.1.4. Introduction to yeast tubulin genes 
 
The S. cerevisiae TUB2 gene encodes the single essential β-tubulin of yeast (Neff et 
al. 1983). Tub2p belongs to the tubulin superfamily, which, in addition to β-tubulin, 
includes α-tubulin (TUB1 and TUB3) (Schatz et al. 1986a, b) and γ-tubulin. β- and α-
tubulin form tubulin heterodimers that polymerise into microtubules. Yeast tubulin 
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shows about 75% homology to human brain tubulin (Barnes et al. 1992). All 
microtubules in S. cerevisiae emanate from a microtubule-organising centre called 
the spindle pole body (SPB) that is embedded in the nuclear envelope (Knop et al. 
1999). There are several synthetic lethal interactions with either α- or β-tubulin in 
yeast. A strain that lacks the Mitotic Arrest Deficient 2 (mad2∆) gene is known to 
have synthetic lethal interactions with either of the two main tubulin genes in yeast 
(Hardwick et al. 1999; Parsons et al. 2004). This gene is a component of the spindle-
assembly checkpoint complex that delays the onset of anaphase in cells with defects 
in mitotic spindle assembly. The haploid deletion mutant (mad2∆) strain was used in 
this study as a background strain, because earlier studies showed this strain was 
sensitive to PelA at much lower concentrations than the haploid wild type strain 
(BY4741) (Wilmes PhD thesis, 2008).  
 
2.1.5. Introduction to other microtubule-stabilising agents  
 
Microtubules play key roles in many cellular processes including cell division. 
Normal cell division is dependent on the dynamic instability of microtubules during 
the course of mitosis and cytokinesis. Interruption of microtubule dynamics has 
proven to be an effective target for cancer chemotherapy (Wilson and Jordan, 1995). 
Microtubule-stabilising agents (MSA) bind to polymerised tubulin and stabilise the 
microtubule spindles, leading to mitotic arrest followed by cell death. The growing 
clinical expediency of the taxoids (Eisenhauer and Vermorken, 1998) and the 
discovery of new natural products such as the epothilones (Bollag et al. 1995), 
laulimalide (Mooberry et al. 1999), and PelA (West et al. 2000) with the same 
mechanism of action have all occurred simultaneously. The key aspect of the 
mechanism of action of the different MSA is the binding of these compounds to 
microtubules, resulting in stabilisation of the tubulin polymers (Schiff et al. 1979) 
and blocking of their dynamic properties (Derry et al. 1995). Cells exposed to such 
drugs are unable to form a normal mitotic spindle, cannot divide after DNA 
replication, and soon undergo apoptosis.  
 
Laulimalide is a cytotoxic natural product that acts like other MSA. The compound 
enhances tubulin assembly, and laulimalide is quantitatively comparable to paclitaxel 
in its effects on the reaction. Laulimalide is also active in Pgp overexpressing cells in 
which paclitaxel is ineffective. Previous studies have shown that laulimalide and 
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paclitaxel probably bind at different sites on the tubulin polymer (Pryor et al. 2002). 
Mooberry et al. (1999) reported that laulimalide induced tubulin assembly, caused 
cells to accumulate at the G2/M phase of the cell cycle, and caused paclitaxel-like 
microtubule bundles to appear in cultured cells.  
 
The epothilones have also generated significant interest, as they also retain activity 
against paclitaxel-resistant cell lines (Bollage et al. 1995; Kowalski et al. 1997; Ter 
Haar et al. 1996). Ixabepilone (aza-EpoB) is the first epothilone analogue that has 
made it into the clinic (Ixempra®, Bristol-Myers Squibb). Although having a similar 
mode of action to paclitaxel, ixabepilone is structurally distinct from the taxanes and 
therefore has unique properties. Importantly, ixabepilone binds to the taxoid-site but 
has reduced susceptibility to the drug efflux transporter Pgp, which is frequently 
associated with multidrug resistance and limits the effectiveness of taxanes, vinca 
alkaloids, and other chemotherapeutic agents (Lee et al. 2008).  
 
2.1.6. Aims of this chapter 
 
To date there still uncertainty as to the location of the PelA binding site. Some 
computer modelling suggested that it is on β-tubulin (Huzil et al. 2008); however, 
previous modelling studies have suggested that the site is on α- not β-tubulin (Pineda 
et al. 2004; Jimenez-Barbero et al. 2006). Sorting out of this controversy is one of the 
aims of this thesis.  
 
The first aim of this chapter is to test whether PelA binds to yeast tubulin at the site 
proposed by Huzil et al. (2008) and to determine if a mutation of the specific amino 
acids at this site will generate resistance to the action of the drug. This will advance 
our understanding of the PelA binding site on mammalian tubulin. To achieve the 
first aim, yeast will be used to map the key amino acids that play an important role in 
the binding of PelA to yeast tubulin. Using site-directed mutagenesis at single amino 
acid sites likely to be involved in PelA binding (e.g. A296 and R306 of β-tubulin), 
we will be looking at validating the effect of mutations of these amino acids on yeast 
sensitivity to PelA.  
 
The second aim is to take advantage of PelA modelling studies to test other 
mutations that would be predicted to affect PelA binding to β-tubulin, based on the 
modelling of Huzil et al. (2008) and Snyder and Thepchatri (unpublished data). 
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However, some but not all amino acids that confer resistance to PelA will also confer 
resistance to laulimalide. It would be interesting to test mutations in both α- and β-
tubulin to see which set of mutations lead to PelA resistance, but this would be 
beyond the scope of an MSc project. We therefore concentrated on the proposed β-
tubulin site, in part because of the existence of two mammalian cell lines that linked 
mutations at this site with PelA resistance in mammalian cells. Since site-directed 
mutagenesis would be very difficult to carry out in mammalian cells, we used yeast 
as our model organism.  
 
The third aim is to examine the differences in the binding interactions between 
different MSA by testing other MSA, such as laulimalide and epothilone, cross-
resistance in the PelA-resistant colonies. Mapping the PelA-tubulin binding site in 
yeast will enhance our understanding of the MSA interactions with mammalian 
tubulin. Unfortunately, paclitaxel cannot be tested since it is ineffective in yeast 
without humanising the taxoid site sequence of β-tubulin (Bode et al. 2002; Gupta et 
al. 2003). 
 
Our fourth aim is to provide some growth-independent evidence that PelA effects are 
at the level of the microtubules and not some other unrelated target. We will 
therefore look for changes in microtubule morphology by confocal microscopy and 
examine cell cycle block by bud index measurements, and flow cytometry to provide 
more direct evidence that PelA targets tubulin in yeast and is not affecting growth by 
a microtubule-independent mechanism. 
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2.2. Materials and Methods 
 
2.1.1. Compounds 
 
PelA and laulimalide were provided by Assoc Prof Peter Northcote, School of 
Chemical and Physical Sciences, Victoria University, Wellington. Ixabepilone (aza-
epothilone, a derivative of epothilone B) was purchased from Bristol-Myers Squibb 
(NZ) Limited, 88 Shortland Street, Auckland. Marine sponges (Mycale hentscheli) 
containing PelA were collected from Pelorus Sound, Marlborough Sounds, NZ, and 
PelA was purified from the sponges as previously described by West et al. (2000). 
Laulimalide was purified from Cacospongia mycofijiensis sponges collected from 
'Eua, Tonga. All drugs were dissolved in DMSO at 10 mM and stored at -80ºC.  
2.2.2. Yeast strains used in this study 
 
ORF Strain Genotype 
YCG160 BY4741 MAT a ura3∆0 leu2∆0his3∆1 met15∆1 
YJL030W mad2∆ MAT a mad2∆::G418 ura3∆0 leu2∆0his3∆1 met15∆1 
YCG141 pdr1∆ MAT alpha pdr1∆:: NAT can1∆::STE2pr-HIS5 
lyp∆1::STE3prLEU2 ura3∆0 leu2∆0 
YOR153W pdr5∆ MAT a pdr5::G418 ura3∆0 leu2∆0his3∆1 met15∆1 
YCG198         pdr1∆ & pdr3∆ MAT alpha pdr1∆::NAT pdr3∆::URA3 can1∆::STE2pr-Sp_HIS5 
lyp1∆::STE3pr_LEU2 his3∆1 leu2∆0 ura3∆0 
YML124C TUB3-GFP MAT a TUB3-GFP ura3∆::NLS-RedStar2::hph lyp1∆0::mCherry-
NAT his3∆1 met15∆0 leu2∆0  
 
All haploid deletion mutant strains, as well as the haploid wild type (BY4741), were obtained from a  
-80ºC glycerol freezer stock, and streaked out on 10 cm yeast extract peptone dextrose plates (YPD: 
see Appendix I) or synthetic complete plates (SC: see Appendix I) supplemented with the appropriate 
antibiotics for growth selection (200 µg/mL G418 antibiotic (Geneticin, Gibco, Invitrogen) and/or 100 
µg/mL nourseothricin (NAT) antibiotic (Werner BioAgents)). Once strains were streaked, the plates 
were incubated at 30ºC (Contherm Digital Incubator) for 48 hr to allow the yeast to grow, and then the 
plates were kept at 4°C. The background strain of the haploid deletion mutant strains listed above is 
the haploid wild type (BY4741). The deletion mutant strains pdr5∆ and mad2∆ were part of the yeast 
genome deletion collection obtained from Open Biosystems. 
 
2.2.3. Primer design of PelA-resistant tubulin (TUB2) mutants by 
overlap PCR 
 
To insert a mutation in the TUB2 gene by overlap PCR, a set of point mutation 
primers were designed for each mutation as follows. Overlap PCR was used to 
introduce the desired point mutation into the yeast genome at the TUB2 locus, and to 
insert the NatMX cassette (selectable marker) ~ 300 bp downstream (3’ end) of the 
TUB2 gene. The seven site-directed point mutations were A296T, R306H, 
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A296T+R306H (double mutant), R282Q, Q291M, V333W and N337L. For each 
point mutation, a 5’→3’ primer A (all primer sequences are in Appendix II) was 
designed to have 45 bp homology with the TUB2 gene. This is the minimum length 
for effective homologous recombination to occur for the introduction of the point 
mutation into the yeast genome (Fig. 2.2.1 shows a schematic view of the overlap 
PCR technique). A 3’→5’ primer B (primer B is complementary to primer C) was 
designed to have 21 bp homology to NatMX cassette plus 25 bp homology to 
genomic DNA downstream of the TUB2 gene. Two insertion primers (primer C and 
primer D) were designed to have 21 bp (22 bp for primer D) sequence homology to 
the NatMX cassette plus 25 bp (45 bp for primer D) homology to genomic DNA 
downstream of the TUB2 gene. NatMX encodes a nourseothricin (NAT) antibiotic 
resistance marker that is used as a standard selection agent for molecular genetic 
research work (Werner BioAgents). PCR amplification was carried out using purified 
plasmid p4339 (refer to Appendix III) containing the NatMX cassette as a template. 
The PCR products were used to transform the haploid starting strain mad2∆. PCR 
was carried out in a 0.2 mL Thermo Scientific ABgene PCR tube using a PCR 
Thermal Cycler (Eppendorf Mastercycler EP® gradient S-96 well, Germany). The 
PCR cycling times were done according to the method of Janke et al. 2004: 15 min 
of initial activation at 95ºC, followed by 10 cycles of: 1 min of DNA denaturation at 
97ºC, 30 s of annealing at 56ºC, and 2 min and 40 s of extension at 68ºC. This is then 
followed by another 25 cycles of: 1 min of DNA denaturation at 97ºC, 30 s of 
annealing at 56ºC, and 2 min and 40 s of (with the addition of 20 sec/cycle) 
extension at 68ºC. Once the 35 amplification cycles finish, a final 10 min of 
extension at 72°C, and pause at 4°C. Following PCR, 5 µL of each PCR product was 
electrophoresed on a 1% agarose gel for 1 hr at 100 V. The PCR reaction was 
performed by means of a Qiagen HotstarTaq DNA polymerase kit using the 
following reaction conditions: 
 
Reagents    Amount (µL)    Final Concentration 
10 x PCR buffer              5   1x 
dNTPs Mix (20 mM)            1   0.4 mM 
Forward Primer (100 µM)            1   2 µM 
Reverse Primer  (100 µM)            1    2 µM 
Hotstar Taq enzyme (5 U/ µL)          0.5   2.5U/ reaction 
DNA Template             1   - 
Distilled water          40.5   - 
 
Total           50 µL 
 
 
  Source of DNA template: NatMX cassette (p4339 plasmid) or MATa (BY4741), DNA purification was accomplished using 
a MasterPureTM Yeast DNA Purification Kit according to the manufacturer’s protocol. 
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PCR amplification program (Janke et al. 2004) 
 
 
These special conditions were specifically used for the amplification of NatMX cassettes (figure 
adopted from Janke et al. 2004). 
 
 
 
Figure. 2.2.1. Schematic view for overlap PCR. (i) Experimental schematic procedure was used to 
insert the NatMX cassette into the yeast genome downstream TUB2 gene. (ii) The two overlap PCR 
reactions were carried out separately. The first reaction (primers A and B) was designed to introduce 
the point mutation, and the second PCR reaction (primers C and D) was designed to amplify and insert 
the NatMX cassette. The two PCR products were then inserted into the yeast genome at the TUB2 
locus by allowing homologous recombination to occur.  
(i) 
(ii) 
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2.2.4. Transformation 
High efficiency transformation protocol was performed according to the method of 
Gietz and Woods (2002). Briefly, to generate transformants, a single colony of the 
haploid starting strain mad2∆ was inoculated into a BD Falcon™ 50 mL conical tube 
with 10 mL YPD medium and grown overnight at 30˚C on a shaker (Edwards 
Instrument Company, Australia). The next morning, the cells were diluted by 
pipetting 5 µL, 10 µL, or 15 µL into 50 mL YPD in three separate conical flasks and 
grown for 18 hr at 30˚C on a shaker. When the cells had grown to give an OD of 1-2 
at 600 nm wavelength, 10 mL of the cells were pelleted in a benchtop Eppendorf 
centrifuge (Model 5810R) for 5 min at 2500 rpm. After discarding the supernatant, 
the cells were washed twice in dH2O and resuspended in 500 µL dH2O in an 
Eppendorf tube. Li-PEG solution (276 µL) (1.2 mL 90% PEG (50% w/v), 0.15 mL 
dH2O, and 0.15 mL 1 M LiAc) was added to the pelleted cells, and the suspension 
was mixed by pipetting the solution gently. Then 50 µL of salmon sperm DNA 
(salmon sperm DNA at a concentration of 90 mg/mL was boiled for 10 min and 
stored on ice) and 34 µL (10 µL of each of the PCR products + 14 µL of dH2O) of 
PCR product were added to the Li-PEG mixture. The solution was then heat-shocked 
in a 42˚C water bath for 40 min. At the end of the heat-shock treatment, the cells 
were spun down at maximum speed in an Eppendorf Centrifuge (Model 5415R) for 1 
min, the supernatant was removed by pipette, and the pellet was re-suspended in 1 
mL YPD and incubated at 30˚C for 2 hr. After 2 hr, the cells were spun down at 
13,000 rpm, the supernatant was removed and the pellet was re-suspended in 250 µL 
YPD. Transformed cells were plated on a selection plate (YPD+ ClonNAT 200 
mg/mL) and left to grow in a 30˚C incubator for 2 days.  
 
2.2.5. Confirmation PCR primer design 
 
In order to confirm the successful transformant colonies, colony PCR was used. The 
growth of transformed cells on a selection plate (YPD+ ClonNAT 200 mg/mL) was 
excellent evidence that the transformation efficiency was very high; however, 
confirmation via a colony PCR approach is more reliable and further confirms that 
the transformed colony has the desired point mutation. It also reduces the amount of 
PelA needed since its resources are very limited. The advantage of this technique is 
that it does not require genomic DNA purification of individual colonies. For this 
PCR, two transformation confirmation primers were designed as follows: from the 
3’→5’ end of the gene, two primers were designed. The first primer was designed to 
start at the changed amino acid (i.e. at the po
have the point mutation base pairs ( P.µ primer) or designed similarly but with the 
wild-type sequence (WT primer) i.e. having the normal 
the point mutation sequence
each primer was 18 bp. 
18 bp forward primer was designed 
gene). Fig. 2.2.2 shows a schematic view of the primer design. 
Figure. 2.2.2. Schematic view of colony PCR primers
for each point mutation either to carry that point
primer, the forward primer, was designed to go in the forward direction 
upstream (5’→3’) of the point mutation.
 
The strains with the desired point mutation 
glycerol solution and stored at 
2.2.6. Transformation confirmation by colony PCR
 
Using a Pipetman tip, a small portion of a randomly chosen colony was transferred 
into an Eppendorf tube containing 10 µL of 1
Zymolyase dissolved in 1 ml of 2 M sorbitol (AMS Biotechnology (Europe) Ltd)
Zymolyase, purified from culture fluid of
activity against living yeast cell walls 
was incubated at 30°C for 15 min. The PCR cycling times were as follow: 15 min of 
initial activation at 95ºC, followed by 30 cycles of: 1 min of DNA denaturation at 
95ºC,  30 s of annealing at 54ºC and 
min of extension at 72ºC, and finally pause at 4°C. For each colony two reactions 
were prepared, one with the wild type primer and one with the point mutation primer.  
Two µL of the Zymolyase solution was use
and added to the following reaction mixture:
 
 
int mutation) and was designed to either 
TUB2 sequence rather than 
 (all primer sequences are in Appendix II
Approximately  400 bp up-stream of these reverse primers, 
(5’→3’ to go in the forward direction of the 
 
. Two reverse primers 
 mutation or to have the wild-type sequence. Another 
 
were inoculated into 1 ml
-80°C and are presented in Appendix IV.
 
 mg/mL of Zymolyase 20T (1 
 Arthrobacter luteus
(www.amsbio.com). The Zymolyase solution 
1 min of extension at 72ºC, then followed by 10 
d as a DNA template for each reaction 
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). The length of 
a 
 
(3’→5’) were designed 
approximately 400 bp 
 of 25% 
 
mg/ml 
). 
, has strong lytic 
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Reagent     Amount (µL)         Final concentration 
 
10 x PCR buffer            2    1x 
dNTPs mix (20 mM)         0.4    0.4 mM 
Forward Primer (50 µM)        0.4    1 µM 
Reverse Primer (50 µM)        0.4    1 µM 
Hotstar Taq enzyme (5 U/µL)        0.1    0.5U/reaction 
DNA Template                2    - 
Distilled water        14.6    - 
 
Total       20 µL 
 
Following PCR, 5 µL of each PCR product was electrophoresed on a 1% agarose gel 
for 40 min at 100 V. Colonies that showed the correct band size (Fig. 2.3.3- 2.3.9) 
were subjected to another colony PCR experiment to confirm their status before been 
tested for resistance to PelA in a half-log dose-response experiment. 
 
Colony PCR amplification program 
 
 
 
2.2.7. Half-log dose-response curves  
 
For all dose-response experiments, a single colony was inoculated in 2 mL SC 
medium (Appendix I) supplemented with 2% glucose and grown overnight using a 
Glascol® rotator (TotalLabSystems) set to a speed of 50 rpm. For the haploid wild 
type strain (BY4741), 25 mM of HEPES was included with the drug to adjust the pH 
of the medium to approximately 6.5; therefore, creating a better growth conditions 
during drug treatment. The following day, the number of cells in the cultures was 
determined using a haemocytometer, and the cultures were diluted in 10 mL medium 
(YPD or SC) to a final cell concentration of 5 x 105 cells/mL. Then, 100 µL of the 
diluted cells were plated out in BIOFIL® tissue culture 96-well plates, giving a final 
concentration of 5 x 104 cells per well. Cells were treated with 50 µM PelA or 1% 
DMSO (control/solvent) for 18 hr at 30ºC in a Contherm Digital series incubator 
(Contherm Z011, Contherm Scientific Ltd, New Zealand). 
vortexed at 1000 rpm
plates was read at 600 nm 
Molecular Devices, Sunnyvale, CA). The % residual growth was calculated as
[(mean exp abs - background) / (mean 
With mean control abs = average DMSO absorbance
absorbance. 
 
2.2.8. Bud index assay 
 
To determine whether the PelA mode of action in yeast i
phase of the mitotic cell cycle, a bud index assay was carried out. This assay was 
done within the mad2
supplemented with 2% glucose and grown at 30°C overnight using a Glascol
(TotalLabSystems) set to a speed of 50
haemocytometer and diluted to obta
(Amberg et al. 2005). Cells were then incubated at 30°C for 4 hr, following which 
100 µL aliquots were transferred to the wells of a 96
aliquots, 40 µM PelA or 
incubated at 30°C for another 4 hr. 
in a haemocytometer, under an Olympus CX41 phase
at 40x, from each of the drug
phases of the cell cycle by their bud morphology (Fig. 2.2.3). Images of the cells 
were taken with an Olympus AX70 light microscope with brightfield and phase 
contrast, at 100x (oil immersion) magnification. Before observing them under 
microscope, a 2-5 µL aliquot of the culture was placed on a slide, and the cover slip 
was sealed with clear nail polish.
Figure. 2.2.3. Correlation of yeast bud index with cell cycle phases
in the G1 phase of the cell cycle. Cells at stage 2 have a tiny bud, and this stage is equivalent to the S phase. Cells at 
stage 3 have a medium size bud, and cells at stage 4 have a large bud size compared to the previous stages. G
block occurs between stage 3 and 4
 
After 18 hr, plates were 
 for 15 sec to resuspend the culture, and the absorbance of the 
wavelengths on a multiwell plate reader (Versamax, 
control abs - background)] x 100 
, background = average empty well 
 
nvolved 
∆ background strain by inoculation in 2.5 mL SC medium 
 rpm. The next day, cells were counted using a 
in cells in mid-log phase (1
-well plate. To the 100 µL 
1% DMSO (control) was added, and the cells were 
Approximately 350 cells were counted at random 
-contrast, confocal microscope 
-treated and control wells and classifie
  
. Stage 1 has no bud, indicating that the cell is 
. 
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2.2.9. Flow cytometry analysis 
 
Along with the bud index determination, and to further validate the mode of action of  
PelA in yeast i.e. that PelA blocks cells at G2/M, a flow cytometry assay was carried 
out to quantify the amount of DNA present in the treated versus the untreated cells. 
Flow cytometry is commonly used to distinguish growing cells in different phases of 
the cell cycle (Haase and Reed, 2002). In 2 mL SC medium, the haploid strain 
(mad2∆) was inoculated and supplemented with 2% glucose. The cells were grown 
at 30°C overnight in a Glascol® rotator (TotalLabSystems) set to a speed of 50 rpm. 
The next day, cells were counted using a haemocytometer and diluted to 1-2 x 107 
cells/mL to obtain cells in mid-log phase (Amberg et al. 2005). Diluted cells (500 
µL) were then incubated for 4 hr with 40 µM PelA or 1% DMSO (control) and were 
grown for either 6 hr or overnight in a 30° C shaker. The rest of the experiment was 
performed following the method of Haase (2003). In brief, cells were harvested by 
centrifuging at 4000 rpm for 5 min and washed twice with 5 mL Tris buffer (50 mM 
Tris/ HCl, pH 7.5). The cells were then re-suspended in 1.5 mL of distilled water, 
and 3.5 mL of 100% ethanol was added for 1 hr at room temperature (to fix the 
cells). The ethanol was removed by centrifugation followed by pipetting off the 
supernatant, and the cells were resuspended in 5 mL Tris buffer. In order to each to 
separate the cells, they were sonicated in an Ultrasonic Elma® T460 sonicator 
(Global Science) 3x for 5-10 sec. Two mL of 1x RNAse solution was added, and the 
samples were incubated for 1 hr at 37°C in a shaker at 250 rpm (Edwards Instrument 
Company, Australia). Samples were then treated for 5 min with 2 mL of freshly 
prepared pepsin solution (50 mg of pepsin (Sigma) dissolved in 10 mL dH2O plus 45 
µL of concentrated HCl). Cells were then stained with 2 µM SYTOX green (to stain 
the DNA) and were collected for analysis in a FACS Cellquestpro machine (Becton 
Dickinson, Franklin Lakes, NJ, USA). Cell cycle analysis was performed using BD 
Cell Quest™ Pro software (Becton Dickenson). Histogram analysis was used to plot 
the number of cells against the stain intensity, and cells were grouped into G1, S, and 
G2/M phase according to the amount of DNA that was present in the cells. 
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2.2.10. Morphological changes of polymerised α-tubulin in TUB3-
GFP in response to PelA 
 
The haploid TUB3-GFP strain (that also has RFP associated with a nuclear marker 
and mCherry associated with a cytoplasmic signal) was used in this part of the study. 
Dr. David Maass of the Chemical Genetics Laboratory, School of Biological 
Sciences, Victoria University, Wellington, constructed this strain. A single colony 
was inoculated into 50 µL SC medium plus 2% glucose in a well of a Perkin Elmer 
CellCarrier 384-well black, clear bottom plate without a lid (Perkin Elmer 6007439). 
Cells were incubated with and without 50 µM PelA for 4-6 hr in a 30°C incubator. 
During the incubation, images were captured with a Perkin Elmer Evotec Opera 
Fluorescent Confocal Microscope (Opera™, Alphatech System Limited, Auckland, 
New Zealand), with two light filters from two cameras (camera 1: 520/35; camera 2: 
600/40). Laser excitation wavelengths were 488 nm (GFP) and 561 nm (RFP), 
magnification was 60x water immersion (60xW_NA=1.2), and the exposure duration 
was 400 millisecond. At 5-10 hr intervals, the fluorescence of the cells was analysed 
using Evotec Acapella image analysis software. The haploid TUB1-GFP strain was 
also examined under the Opera laser confocal microscope, but the analysed images 
that were taken were not very informative, and PelA did not seem to be effective 
against this strain. In addition, the yeast cells were blurry, possibly due to differences 
in the response of the two strains to the medium and/or the drug, or due to 
experimental error (incorrect focusing or laser intensity). Technically the amount of 
GFP-protein that is expressed from either TUB1 or TUB3 α-tubulin protein should be 
approximately equivalent (Carminati and Stearns, 1997).  
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2.3. Results 
2.3.1. Site-directed mutagenesis and transformation confirmation by 
colony PCR  
 
The PCR products that were generated by site-directed mutagenesis for all point 
mutations were confirmed by agarose gel electrophoresis (Fig. 2.3.1 and Fig. 2.3.2). 
Six (and one double mutant) point mutations were generated in this study. The first 
two were A296T and R306H (and the combined double mutant) which are known to 
confer resistance to PelA in mammalian ovarian carcinoma cells. These amino acids 
are highly conserved between yeast and mammalian cells. Four other point 
mutations, besides the A296T and R306H mutations, were transformed into yeast 
genome based on predictions of PelA-β-tubulin interactions from computer 
modelling studies of Snyder and Thepchatri (unpublished data), and with the help of 
Assoc Prof Paul Teesdale-Spittle of the School of Biological Sciences, Victoria 
University of Wellington. These point mutations were Q291M, N337L, and V333W 
plus one negative control that was known to confer resistance to epothilone B in 
mammalian cells, but not to PelA, R282Q. These amino acids are also highly 
conserved between yeast and mammalian tubulin. The fragment sizes of PCR 
products were within the expected range of 650-775 bp for TUB2 mutations (sizes 
varied depending on the position of the amino acid) and 1200 bp for NatMX cassette. 
PCR products were then transformed into the yeast genome, and colony PCR was 
used to confirm the transformation (Fig. 2.3.3- Fig. 2.3.9). Fragment sizes of colony 
PCR products were within the expected range of 400-500 bp (sizes varied depending 
on the position of the amino acid). For each point mutation transformation, at least 
one colony was identified. To identify a transformed colony, about 30-50 colonies 
needed to be screened for each point mutation to get the right colony that had the 
right point mutation.  
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Figure. 2.3.1. Confirmation of A296T point mutation, R306H, double mutant, 
and NatMX cassette PCR products  
 
           
 
PCR product fragment size for mutant primer sets and the NatMX cassette. Lane 1= 1 Kb plus 
DNA ladder, Lane 2= A296T PCR product, Lane 3= R306H PCR product, Lane 4= the combined 
double mutant PCR product, Lane 5= NatMX PCR product, Lane 6 & 7= negative controls (tubes 
with only PCR mix and no DNA template i.e. NatMX or BY4741 DNA). Fragment sizes were in the 
expected range: 750 bp for TUB2 mutations and 1200 bp for NatMX. 
 
 
Figure. 2.3.2. Confirmation of PCR products of predictive point mutations and 
NatMX cassette PCR products  
 
                                  
 
PCR product fragment size for predictive mutant primer sets and the NatMX cassette.  Lane 1= 
1 Kb plus DNA ladder, Lane 2= R282Q PCR product, Lane 3= Q291M PCR product, Lane 4= 
V333W PCR product, Lane 5= N337L PCR product, Lane 6= NatMX PCR product, and Lane 7= 
negative control (no DNA). Fragment sizes were at the expected range between 650-775 bp for TUB2 
mutations and 1200 bp for NatMX. 
-Ve 
+Ve 
-Ve 
+Ve 
1 Kb Plus Ladder 
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Figure. 2.3.3. Colony PCR for A296T transformation confirmation  
   
 
  
           
 
Transformation confirmation by colony PCR for A296T point mutation. Two primers were used for 
the confirmation of A296T mutant colonies. Along with the forward primer that was designed, to be 
400 bp upstream of the desired point mutation, the reverse primer was designed to have either the WT 
sequence or the point mutation. Two PCR reactions were performed for each colony picked at 
random, so that if transformation had occurred, a band would only be present if the colony had the 
expected WT sequence or the expected point mutation for the primer set used. Only colony #1 has the 
successful point mutation (red box), with a product for the mutant primer set but not the wild type 
primer set.  
 
 
Figure. 2.3.4. The confirmation R306H transformation by colony PCR  
 
 
                   
 
In this figure, colony # 1 shows the correct R306H point mutation (blue box). For more details on the 
primer sets used, see Fig. 2.3.3 legend.  
 
 
 
 
-Ve 
+Ve 
-Ve 
+Ve 
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Figure. 2.3.5. Confirming R306H+A296T transformation via colony PCR  
 
                             
 
Colony # 3 has the correct point mutations A296T+ R306H (olive green box). 
Figure. 2.3.6. Transformation confirmation for R282Q by colony PCR  
 
          
  
In this confirmation, two mutant colonies were recovered via colony PCR.  Colony # 3 (orange box) 
and # 4 (yellow box) have the correct R282Q point mutation. 
Figure. 2.3.7. The confirmation for Q291M transformation by colony PCR  
 
               
-Ve 
+Ve 
-Ve 
+Ve 
-Ve 
+Ve 
This figure shows that colony # 3 has the correct Q291M mutation (blue box) that was transformed 
into the yeast genome. 
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Figure. 2.3.8. Confirmation of V333W transformation via colony PCR  
 
 
                   
 
 
The image above shows that colony # 4 has the right V333W mutation (light orange box) that was 
successfully transformed into the genome. 
  
Figure. 2.3.9. N337L transformation confirmation via colony PCR  
 
                  
                 
 
Colonies # 1 (light purple box) and # 4 (white box) both have the correct N337L point mutation. 
 
 
 
 
 
 
 
-Ve 
+Ve 
-Ve 
+Ve 
- 38 - 
 
2.3.2. Half-log dose-response curves for mutant strains treated with 
PelA  
 
Testing for growth inhibition in wild type and deletion mutant strains  
 
In preliminary experiments, the haploid wild type strain (BY4741) along with several 
haploid deletion mutants were tested (Fig. 2.3.10) to determine whether PelA could 
inhibit growth of these strains. The results from these experiments for the wild type 
and mad2∆ were consistent with other results that were obtained from earlier studies 
carried out by Anja Wilmes in her PhD research (Wilmes PhD thesis, 2008). The 
wild type strain was inhibited by approximately 50% at the highest drug 
concentration (50 µM PelA), and mad2∆ growth was inhibited by 94% with an IC50 
value of 36 ± 1 µM. The most sensitive strain amongst the deletion mutants that were 
tested were the pleiotropic efflux pumps regulators (transcription factors) PDR-
deficient strain (pdr1∆ & pdr3∆) with 93% growth inhibition and IC50 value of 22 ± 
1 µM, and the pleiotropic efflux pumps deletion mutant strain pdr5∆ with 92% 
growth inhibition and IC50 value of 29 ± 1 µM. Growth inhibition measurements for 
the other deletion mutant strains are presented in Table. 2.3.1, and calculated IC50 
values are presented in Table. 2.3.3. It is worth noting that pump knockout deletion 
strains residual growth were similar to mad2∆, which makes them good candidates 
for future site-directed mutagenesis experiments.  
 
Testing for resistance in PelA-tub2-mutant strains 
The tub2 mutant strains that showed the correct point mutation were then subjected 
to half-log dose-response analyses to examine their sensitivities to PelA. All the 
generated mutant strains were treated with the highest PelA concentration (50 µM) 
(Fig. 2.3.11-2.3.12).  
 
a) Effect of A296T and R306H point mutations on growth responses to PelA 
 
The single amino acid mutations A296T and R306H (and the combined double 
mutant) all were resistance to PelA in yeast (Fig. 2.3.11) with IC50 values > 50 µM, 
suggesting that homologue mutations retain resistance in yeast. This compares to the 
sensitive strain mad2∆ whose growth was completely inhibited at 50 µM. The effect 
of the two individual point mutations (A296T and R306H) was consistent with that 
seen in mammalian cell lines (Wilmes PhD thesis, 2008). In PelA-R1 cells an amino 
acid change at position 296 in β-tubulin from alanine to threonine resulted in 5-fold 
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resistance to PelA compared to the parental 1A9 cells, and the single amino acid 
mutation R306H gave L4 40-fold resistance.  
 
b) Effect of predicted point mutations on growth responses to PelA 
 
The results for the point mutations predicted from modelling, on the other hand, were 
not as expected. Q291M and N337L were predicted to give resistance to PelA, but 
only N337L gave resistance with IC50 values > 50 µM. This compares to the 
sensitive strain mad2∆ whose growth was completely inhibited at 50 µM PelA (Fig. 
2.3.12). V333W was predicted to give resistance to laulimalide but have little effect 
on PelA, and R282Q should have been a neutral mutation for PelA but should confer 
resistance to EpoB. V333W colony was resistance to PelA, despite no resistance 
being expected, with IC50 values > 50 µM, compared to the sensitive strain mad2∆ 
whose growth was completely inhibited at 50 µM PelA. R282Q unexpectedly 
conferred resistance to PelA, also an unexpected result, with IC50 values > 50 µM. Its 
effect on ixabepalone responses could not be measured as ixabepilone has no effect 
on yeast growth (Fig. 2.3.13). At the highest PelA concentration (50 µM), almost all 
mutant strains were therefore PelA-resistant i.e. they grew with and without the drug; 
whereas, the mad2∆ strain showed almost no growth in the presence of the drug. 
Only strain Q291M was sensitive to PelA, although it had been predicted that it 
would confer resistance on the cells. This indicates that the change in this particular 
residue did not confer resistant to the drug. 
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Figure. 2.3.10. Sensitivity of wild type, mad2∆, and pump knockout mutants to 
PelA  
 
 
Half-log dose-response curves for the haploid wild type BY4741 (WT), and the deletion mutant 
strains pdr5∆, PDR-deficient strain (pdr1∆ & pdr3∆), and mad2∆. These strains were treated with 
PelA at concentrations up to 50 µM for 18 hr. At 50 µM PelA, the WT growth was only inhibited by 
51%; whereas, at the same drug concentration the strains mad2∆, pdr5∆ and PDR-deficient strain 
(pdr1∆ & pdr3∆) growth were inhibited by 92-94%. Refer to Table 2.3.1 for a summary of growth 
inhibition results of these strains. Data are presented as the mean ± SD of three independent 
experiments (n=3 experiments with one biological replicate). IC50 values were calculated are presented 
in Table. 2.3.3. 
 
 
Table. 2.3.1. Percentage of growth inhibition of wild type, mad2∆, and pump 
knockout mutants treated with PelA  
 
Yeast strain % residual growth 
(relative to DMSO-treated cells at 50 µM ± SD) 
 
WT (BY4741) 49.6 ± 0.3% 
mad2∆ 6  ± 1% 
pdr5∆ 8  ± 1% 
pdr1∆ & pdr3∆  7  ± 1% 
 
The haploid wild type strain BY4741 and three haploid deletion strains were treated with 50 µM PelA 
for 18 hr. The percent of growth (relative to DMSO-treated cells) at the highest concentration (50 µM) 
is presented in this table. Please note that the data present in this table are the same results as in Fig. 
2.3.10. IC50 values were calculated are presented in Table. 2.3.3. Data are presented as the mean ± SD 
of three independent experiments (n=3 experiments with one biological replicate).   
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Figure. 2.3.11. Growth inhibition curves of mad2∆ and tub2 mutants treated 
with PelA 
 
 
The three tub2-mutant strains (A296T; R306H; A296T+R306H), and the haploid deletion mutant 
background strain mad2∆ (positive control) were treated with up to 50 µM PelA for 18 hr. At 50 µM 
all three mutant colonies were PelA-resistant i.e. their growth was not inhibited in the presence of the 
drug compared to the positive control (mad2∆). Data are presented as the mean ± SD of three 
independent experiments (n=3 experiments with one biological replicate).   
 
Figure. 2.3.12. Growth inhibition curves of the PelA-predicted point mutations 
and mad2∆ strain 
 
The four predictive tub2-mutant strains (Q291M, N337L, and V333W and R282Q) as well as the 
haploid deletion mutant background strain mad2∆ (positive control) were treated with up to 50 µM 
PelA for 18 hr. Data are presented as the mean ± SD of three independent experiments (n=3 
experiments with one biological replicate). Please note that the mad2∆ growth curve is the same as 
presented in Fig. 2.3.11 and the four mutant curves were determined simultaneously with the other 
three mutant strains, but the results are graphed separately for clarity. 
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2.3.3. The effect of tubulin point mutations on growth responses to 
ixabepilone and laulimalide. 
 
Other MSA were tested to see whether the generated point mutations were PelA-
specific or if there was some overlap with other drugs that bind to the same or a 
different binding site on tubulin. Laulimalide should be more similar in its effects to 
PelA than ixabepalone.   
 
Growth inhibition studies of various Ixabepilone-treated yeast strains 
Ixabepilone (aza-epothilone B) was included as a positive control because its binding 
site (the taxoid site on β-tubulin) is well defined, and it binds to a different site than 
PelA on mammalian tubulin. Epothilone is also known to stabilise yeast 
microtubules in vitro, although it is relatively ineffective in inhibiting yeast growth in 
vivo (Gupta et al. 2003). We obtained similar results to Gupta et al. with growth of 
yeast. Ixabepilone was ineffective against all the yeast strains tested (Fig. 2.3.13) at 
concentrations up to 300 µM. The drug had no effect even in the presence or absence 
of the permeability agent sodium dodecyl sulfate (SDS). SDS is an anionic surfactant 
commonly used in conjunction with polyacrylamide gel electrophoresis. However, it 
has been successfully used as an effective permeabilising agent of yeast cell 
membranes, facilitating the uptake of a drug into the cell (Pannunzio et al. 2004). 
SDS concentrations were recommended by Christina Roberts (Chemical Genetics 
Laboratory, Victoria University of Wellington) who had carried out preliminary 
experiments to determine the SDS concentration that provides the optimal balance 
between permeabilising the membrane and not affecting cell growth. The drug was 
also was not effective against the pump knockout deletion strains. This might 
indicate that ixabepilone has no effect on yeast tubulin or growth.  
 
Growth inhibition studies of various laulimalide-treated tub2-mutant strains 
Laulimalide is a potent MSA that binds to a different site on tubulin to paclitaxel. 
Competition for binding studies has revealed that laulimalide occupies the same or 
an overlapping site with PelA. Dose-response studies were performed with the 
haploid wild type strain (BY4741) along with several haploid deletion mutants (Fig. 
2.3.14) to determine the optimal drug concentration to use and to see if yeast was 
sensitive to laulimalide. Laulimalide proved to be even more potent than PelA. At 50 
µM, laulimalide exhibited about the same level of inhibition of growth as PelA. The 
WT growth was inhibited by 65% with an IC50 value of 36 ± 1 µM; whereas, the 
deletion mutant strain mad2∆ exhibited 92% inhibition at the same drug 
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concentration but with IC50 value of 24 ± 1 µM so it was 1.5 fold sensitive to the 
drug compared to wild-type. The drug seemed to be more potent in the haploid pump 
knockout deletion strains: pdr5∆ and PDR-deficient strain (pdr1∆ & pdr3∆), as their 
growth was inhibited by 93-94% with an IC50 value of 2-3 ± 1 µM. Thus, these 
strains were hypersensitive to laulimalide (Fig. 2.3.14) compared to PelA (Fig. 
2.3.10) and their growth curves were shifted to a lower µM range. For more detailed 
information on growth inhibition values at the maximum laulimalide dose, see Table. 
2.3.2. For more information about the IC50 values that were calculated for each 
strain, see Table. 2.3.3. 
 
Effect of laulimalide on PelA-mutants strains 
Furthermore, the two point mutations known to confer resistance to PelA in 
mammalian cells (A296T and R306H) were also highly laulimalide resistant (Fig. 
2.3.15). At 50 µM laulimalide, the three mutant strains that were resistant to PelA 
were also resistance to laulimalide. The mad2∆ growth was inhibited completely at 
50 µM laulimalide. In the presence of laulimalide, A296T and R306H were 
resistance to laulimalide with IC50 values > 50 µM. The mutant strains growth curves 
were compared to mad2∆ (Fig. 2.3.15).  
 
Moreover, two of the three predicted mutations failed to show resistance to 
laulimalide; thus, laulimalide was not exactly mirroring the effects of PelA. At the 
highest concentration of laulimalide (50 µM), two of the predicted PelA-mutant 
strains were laulimalide-resistant. V333W strain and N337L strain were resistance to 
laulimalide with IC50 values > 50 µM; whereas, the mad2∆ strain showed almost no 
growth in the presence of the drug compared to growth in untreated cells. At 50 µM 
laulimalide, the third predicted mutation (Q291M) behaved in the same manner 
against laulimalide as for PelA i.e. the cells were hypersensitive to the drug, with 
IC50 value of 12 ± 1 µM i.e. 2-fold sensitive to the drug compared mad2∆ control that 
had an IC50 value of 24 ± 1 µM. The R282Q mutation, that was predicted to give 
resistance to epothilone but not to PelA or laulimalide, was semi-sensitive to the 
laulimalide compared to mad2∆. Mad2∆ was completely growth inhibited at 50 µM 
laulimalide. Mutant strain R282Q was sensitive to the drug with an IC50 value of 28 ± 
1 µM (Fig. 2.3.16), indicating that there are some differences in the effects of 
laulimalide relative to PelA since R282Q strain was completely resistant to PelA 
(Fig. 2.3.12).  
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As stated earlier laulimalide was more potent than PelA in several deletion mutant 
strains. The IC50 values showed that laulimalide showed 10-fold the activity of PelA 
in pump knock out deletion strains, 1.5-fold the activity in the mad2∆ strain, and the 
same activity in the haploid wild type strain (BY4741) (Table. 2.3.3). 
Figure. 2.3.13. Growth inhibition curves for yeast strains treated with different 
concentrations of aza-epothilone (ixabepilone) 
 
  
  
  
 
Yeast growth inhibition curves for ixabepilone (single representative experiments) are presented for 
different yeast strains. The haploid wild type (BY4741) strain and the other deletion mutant strains 
mad2∆, pdr1∆, and pdr5∆ were treated with ixabepilone for 18 hr.  
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Figure. 2.3.14. Growth inhibition curves of wild type, mad2∆, and pump mutant 
strains treated with 50 µM laulimalide 
 
 
The half-log dose-response curves for the haploid wild type BY4741 (WT), as well as the deletion 
mutant strains pdr5∆, PDR-deficient strain (pdr1∆ & pdr3∆), and mad2∆ treated with laulimalide for 
18 hr are presented. Refer to Table 2.3.2 for a summary of growth inhibition results at 50 µM. Data 
are presented as the mean ± SD of three independent experiments (n=3 experiments with one 
biological replicate) ± SD. IC50 values were calculated and are presented in Table. 2.3.3. 
 
 
 
Table. 2.3.2. Percentage of growth inhibition of haploid mutant deletion 
strains treated with laulimalide 
 
Yeast strain % residual growth 
(relative to DMSO-treated cells at 50 µM ± SD) 
WT (BY4741) 35 ± 4% 
mad2∆ 8 ± 4% 
pdr5∆ 6 ± 2% 
pdr1∆ & pdr3∆ 7 ± 2% 
 
The haploid strain BY4741 and three haploid deletion strains were treated with 50 µM laulimalide for 
18 hr. The percent of growth (relative to DMSO-treated cells) at the highest concentration (50 µM) is 
presented in this table. Data are presented as the mean ± SD of three independent experiments (n=3 
experiments with one biological replicate). IC50 values were calculated and are presented in Table 
2.3.3. The data presented here are the same as in Fig. 2.3.14. 
 
 
 
 
 
 
 
 
 
- 46 - 
 
Figure. 2.3.15. Growth inhibition curves of mad2∆ and tub2 mutant strains 
treated with laulimalide  
 
 
The three PelA-mutant strains (A296T, R306H, and A296T+R306H), and the haploid deletion mutant 
background strain mad2∆ (positive control) were treated with up to 50 µM laulimalide for 18 hr. Data 
are presented as the mean ± SD of three independent experiments (n=3 experiments with one 
biological replicate).   
 
Figure. 2.3.16. Growth inhibition curves of the predicted tub2 point mutation 
strains treated with 50 µM laulimalide  
 
 
Dose-response curves for laulimalide were generated for the four predictive PelA-mutant strains 
(Q291M, N337L, and V333W and R282Q), and the haploid deletion mutant background strain mad2∆ 
(positive control) treated with up to 50 µM laulimalide for 18 hr. Data are presented as the mean ± SD 
of three independent experiments (n=3 experiments with one biological replicate). Please note that the 
mad2∆ growth curve is the same as presented in Fig. 2.3.15, and the mutant strain curves were done 
along with the other three mutants, but the results are graphed separately for clarity. 
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Table. 2.3.3. IC50 values of yeast strains treated with 50 µM PelA and/or 
laulimalide 
 
 
 
 
 
 
 
 
 
IC50 values were calculated from dose-response curves for both PelA and laulimalide using SigmaPlot 
software (v10.0). 
 
 
2.3.4. The effect of PelA on the yeast cell cycle using bud index and 
flow cytometry assays 
 
To determine the PelA effect on the yeast cell cycle, and to verify whether PelA 
blocks yeast mitotic division at G2/M phase (similar to mammalian cell lines), two 
different assays were carried out. The first assay took advantage of the yeast cell 
cycle analysis. S. cerevisiae divides by budding and shows specific cell bud 
morphologies at different stages of the cell cycle (Qaddouri et al. 2009). Unbudded 
cells are in the G1 phase, small budded cells are in the S phase, and large budded 
cells are in the G2/M phase (Fig. 2.2.3). Thus, it is easy to monitor cell-cycle 
progression by simply observing cells using differential interference contrast 
microscopy. The effect of PelA on the bud index of the haploid deletion strain 
mad2∆ was determined in PelA-treated cells vs. untreated (Fig. 2.3.17). At 40 µM 
PelA, treated mad2∆ cells showed an increase in the stage 4 (large budded cells) 
cells compared to untreated cells. The percentage of cells present in G2/M almost 
doubled in PelA-treated (34 ± 1%) compared to DMSO-treated (control) cells (18 ± 
4%) (Fig. 2.3.18), providing evidence that PelA has a similar mode of action in yeast 
to mammalian cells. A summary of bud-index percentage results is presented in 
Table. 2.3.4.   
 
Another type of cell cycle analysis was then undertaken to determine whether PelA 
causes cell-cycle perturbation by measuring DNA content using Fluorescence-
Activated Cell Sorting (FACS). After 6 hr, PelA caused more cells (53%) to be in 
G2/M in the treated sample compared to the untreated sample (16%) (Fig. 2.3.19), 
demonstrating a blockage at G2/M in the treated sample compared to the untreated 
control, consistent with the bud index results. Two different flow cytometry 
 Drug          PelA Laulimalide     Ratio 
PelA/Lau 
Strains ± SD  
 
49 ± 1 µM 
 
36 ± 1 µM 
 
1 WT ± SD 
mad2∆ ±SD 36 ± 1 µM 24 ± 1 µM 1.5 
pdr5∆ ±SD 29 ± 1 µM 3 ± 1 µM 10 
pdr1∆ & pdr3∆ ±SD 22 ± 1 µM 2  ± 1 µM 11 
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experiments were performed, one in which the yeast cells were treated with 40 µM 
PelA for 6 hr and another in which treatment was for 18 hr. The 18 hr experiment did 
not exhibit block at G2/M in PelA-treated cells relative to DMSO-treated control 
cells (data not presented). 
Figure. 2.3.17. Bud index for 40 µM PelA-treated and untreated mad2∆ cells  
 
Phenotypic analysis of the yeast cell-cycle bud morphology stages. Bud index was measured for the 
growing haploid deletion mutant strain mad2∆. The upper left image shows an untreated sample, and 
a 40 µM PelA-treated sample is shown on the right. There was greater increase in the number of the 
large budded cells (stage 4) -black arrowheads- in the treated sample than in the untreated sample. 
Note that although there appear to be more cells in the treated sample than the untreated sample, the 
difference is due to sample pipetting error and not differences in cell number in the samples. The 
lower image classifies the buds according to their size and to the corresponding phase of the cell 
cycle. Cell cycle stages are 1= G1, 2= S, 3=G2, 4=mitosis (M), and 5= cytokinesis (C). 
Figure. 2.3.18. Budding index histogram for mad2∆ strain treated with 40 µM 
PelA 
  
The haploid deletion mutant mad2∆ cells were treated with 40 µM PelA for 6 hr at 30°C. The 
histogram shows the percentage of cells present in each stage of the cell cycle. Cells were counted in 
each of three experiments for each stage, and the mean of the three independent experiments ± SD is 
presented (n=3 experiments with one biological replicate). Cell cycle stages are 1= G1, 2= S, 3=G2, 
4=mitosis (M), and 5= cytokinesis (C). Refer to Table. 2.3.4 for a summary of bud-index percentage 
results. 
Stage 
, 6hr 
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Table. 2.3.4. Bud-index summary 
 
 
Budding index percentages were calculated for growing mad2∆ cells. There was 2-fold increase in 
cell number in stage 4. Results are presented as the mean of three independent experiments ± SD (n=3 
experiments with one biological replicate). Data are the same as in Fig. 2.3.14.  
 
 
Figure. 2.3.19. Flow cytometry for mad2∆ cells treated with 40 µM PelA  
 
  
               
      DMSO (6 hrs)            40 µM PelA (6 hrs) 
                                             
 
Flow cytometry analysis for the haploid mad2∆ strain treated with 40 µM PelA. After 6 hr, PelA 
caused a 3.5-fold increase in cells to be in G2/M (53%) in the treated sample (red line) compared to 
the untreated sample (16%) (purple shade). Only a single experiment was carried out due to the 
limited supply of the drug. 
 
 
 
 
 
 
 
 
 
 
 
G1 
(Unbudded) 
S 
( small bud) 
G2 
(medium bud) 
M 
(large bud) 
C 
Cytokinesis 
DMSO 37 ± 5% 13 ± 3% 17 ± 3% 18 ± 4% 14 ± 3% 
PelA 26 ± 3% 8 ± 1% 9 ± 2% 34± 1% 8 ± 4% 
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2.3.5. The effect of PelA on microtubule morphology  
 
Reporter proteins are commonly used as markers in biotechnology to study various 
aspects of the gene expression machinery and thereby improve visualisation of gene 
expression. In S. cerevisiae, two genes encode alpha-tubulin: TUB1 and TUB3. 
Unlike TUB1 which is essential for growth, TUB3 is expressed at low levels and is 
not essential for growth. The α-tubulin genes were chosen to be labelled with GFP 
because yeast cells are relatively insensitive to the level of expression of α-tubulin, 
whereas overexpression of β-tubulin is lethal (Burke et al. 1989; Katz et al. 1990; 
Weinstein and Solomon, 1990). TUB1 and TUB3 encode functionally identical α-
tubulin proteins (Schatz et al. 1986b). In this section, a strain of cells that express 
green fluorescence protein (GFP)-TUB3 was used. For reasons unrelated to the 
present study, these cells also express red fluorescent protein (RFP) as a nuclear 
localisation signal and mCherry as cytoplasmic signal (data gathered from the RFP 
and mCherry was not used in this study). Fluorescent cell images were collected in 
an Opera confocal laser microscope. There was a 3-fold increase in the number of 
cells containing microtubular-spindles after treatment with 50 µM PelA for 5 hr at 
30˚C relative to untreated (Fig. 2.3.21). A similar effect was observed after 7 hr, but 
the GFP expression seemed to be lost after 10 hr. The microtubule-spindles were 
more easily visualised in black and white images than in coloured images (Fig. 
2.3.20 vs. Fig. 2.3.21). The spindles were mostly visible in large budded cells in 
which the microtubule spindle is shared between the mother and daughter cells. In 
the PelA-treated sample, the microtubule-spindles were more pronounced or distinct 
compared to the spindles seen in the untreated samples. The percentage of cells with 
spindles vs. non-spindles was calculated manually from visual examination of the 
images (Table. 2.3.5). The number of cells present in the untreated sample ranged 
from 400 to 500 cells per image, and in the treated sample from 600 to 700 cells per 
image. Five images were counted per sample, and all cells in the image were 
included in the analysis. The GFP results are consistent with the bud-index 
experimental results, since an increase in the large budded cells in the bud index 
assay was also seen at G2/M stage.  
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Figure. 2.3.20. Alpha-Tubulin (TUB3)-GFP, RFP and mCherry colour images.  
 
 
 
 
An example of yeast TUB3-GFP and RFP images under the Opera microscope. Cells were treated 
with or without 50 µM PelA. Red fluorescence is the nuclear localisation signal; green labels the 
microtubule-spindles. The spindle in large budded cells can be visualised as an elongated yellow-
green set of spindle fibres surrounded by the red fluorescence of the nucleus. The microtubule-spindle 
is shared between the daughter and the mother yeast cell. Yeast cells at G2/M stage are labelled by 
white arrow heads. Based on two biological replicates. 
 
Untreated (control) 
PelA-treated 
Figure. 2.3.21. Alpha
  
 
The top image shows untreated cells (
treated cells. Cells were treated for 6 hr before taking images. There was an increase in the number of
yeast cells at G2/M stage (white arrows) compared to untreated cells. 
microtubule-spindles that are shared between the daughter and the mother yeast cell. Based on two 
biological replicates. 
-Tubulin (TUB3)-GFP grayscale images 
medium alone), and the bottom image shows 
These large budded cells display 
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50 µM PelA-
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Table. 2.3.5. Percentage of cells with a spindle in PelA-treated and 
untreated TUB3-GFP cells 
 
 Cells with spindle (± SEM) 
Untreated cells 2 ± 1% 
Treated cells  6 ± 1% 
 
The percentage of cells containing cells with a microtubular-spindle in 50 µM PelA-treated vs. 
untreated cultures. There was a 3-fold increase in the number of spindle-containing cells in the PelA-
treated sample compared to the untreated sample. Data are based on the total number of cells counted 
per image from two biological replicates.  
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2.4. Discussion 
Mapping PelA binding-site  
 
To start with, it was important to prove that PelA exerted its effect on yeast growth 
via targeting the microtubules, since a secondary, microtubule-independent target 
could also be involved in its action. It was also very important to at least indirectly 
confirm that PelA actually binds to yeast tubulin in the region predicted by Huzil et 
al. (2008), and therefore mapping the binding site on yeast tubulin would provide 
useful information about the mammalian binding site for PelA. Thus, by mutating 
amino acids in the proposed Huzil et al. binding site, it was expected that the action 
of PelA would be altered, and this would provide indirect evidence that PelA actually 
interacted with β-tubulin in this region. 
 
Site-directed mutations in yeast were based on a computer modelling study being 
carried out by Jim Snyder et al. (unpublished data) at Emory University in Atlanta 
that showed PelA participating in 4 hydrogen bonds to 4 different residues in the 
proposed tubulin-binding site (refer to Fig. 2.1.2 in the introduction section of this 
chapter). Previous studies in mammalian cell lines (Paraskevi Giannakakou, 
unpublished data) showed that a mutation in β-tubulin residue Arg306 to either 
histidine or cytosine resulted in loss of PelA activity, indicating that this residue may 
have a direct interaction with PelA in its binding site. The Snyder group computer 
docking studies suggested that Arg306 interacts with the 7-OMe group of PelA. A 
similar argument applies for Ala296 when changed to threonine (Wilmes PhD thesis, 
2008). Our results were consistent with that seen in mammalian cell lines (Fig. 
2.3.11). 
 
Based on the Snyder model, however, another predicted hydrogen bonding 
interaction that should block PelA binding was Gln291. However, changing Gln291 
to methionine resulted in a hypersensitive colony, rather than a resistant colony. 
Glutamine is an amino acid with a hydrophilic side chain that may interact with PelA 
through H-bonding (from the amide group). The rationale was to change Gln to an 
amino acid that has a hydrophobic side group like Met in order to examine the 
importance of the H-bonding between Gln291 and PelA. Gln291Met resulted in a 
hypersensitive colony (Fig. 2.3.12) (where it was supposed to be resistant due to the 
loss of H-bonding, not sensitive). This might be due to either a lack of H-bond 
interaction between this residue and PelA or a poor choice of the amino acids for the 
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mutation. In the case of another mutation that was expected to reduce PelA binding, 
conversion of Asn337 to leucine, the rationale for the choice was made based on 
changing an amino acid with an H-binding (active amide group in Asn) to some 
other amino acid with no H-binding like Leu. This change resulted in a PelA-
resistant colony (Fig. 2.3.12); thus, the loss of PelA activity (resistance) may indicate 
a direct interaction of this residue with the 2-OH of PelA. According to the Snyder 
model, the C-16 methyl group of PelA may have limited contact with Val333 of β-
tubulin, thus changing it to another amino acid (e.g. Trp) might create a steric clash 
in this area due to the change in the size of the amino acid with Trp being larger than 
Val (Table. 2.4.1.). This alteration was tested in our study, and the mutation 
conferred resistance to PelA (Fig. 2.3.12). It was proposed in the Snyder model, as 
stated earlier, that PelA has only very limited contacts with hydrophobic residues; 
thus, changing the amino acid Val333 to Trp, a large-neutral amino acid, proved that 
loss of the hydrophobic contact reduced the binding of PelA and therefore conferred 
resistance to the drug.  
 
Table. 2.4.1. Amino acids properties used in this study and their phenotype with 
other MSA 
Residues Abbrev. Residue property Altered Residue Abbrev. Residue property 
Effect with other 
MSA (i.e. 
laulimalide) 
Ala296 A 
Acyclic, small, 
neutral, 
hydrophobic 
Thr T Acyclic, medium, 
neutral, polar 
 
IC50 > 50 µM 
 
Arg306 R 
Acyclic, basic, 
charged, large, 
polar, positive 
His H 
Aromatic, basic, 
charged, cyclic, 
large, neutral, 
polar, positive 
 
IC50 > 50 µM 
 
Arg282 R 
Acyclic, basic, 
charged, large, 
polar, positive 
Gln Q Acyclic, neutral, large, polar 
 
IC50 < 50 µM 
    
Asn337 N Acyclic, neutral, 
medium, polar Leu L 
Acyclic, neutral, 
large, aliphatic, 
hydrophobic, 
 
IC50 > 50 µM 
 
Gln291 Q Acyclic, neutral, large, polar Met M 
Acyclic, neutral, 
large, hydrophobic 
  
    IC50 <  50 µM 
        
Val333 V Acyclic, neutral, 
medium, aliphatic Trp W 
Aromatic, neutral, 
large, cyclic, 
hydrophobic 
 
IC50 > 50 µM 
 
This table summarizes the chemical properties of the amino acids that should be involved in PelA 
binding, based on the computer modelling data of Snyder and Thepchatri (unpublished data). It also 
presents the chemical properties of the replacement amino acid in the mutated tubulin. 
 
 
Based on the current Snyder and Huzil models, other residue mutations that might be 
worth exploring are: F296, Y312, Val315, Y342, and V335 since models of 
laulimalide (Thepchatri and Snyder, unpublished data) suggest these residues play an 
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important part in hydrophobic anchoring and suggests that laulimalide is greatly 
affected by these mutations, but PelA is not affected. The Snyder model of PelA 
binding does not propose interactions with any of these residues. If the activity of 
PelA is altered by mutation of these residues, the model will need to be modified to 
reflect these contacts (Thepchatri and Snyder, unpublished data). Perhaps one of 
these would have been a better negative mutation than amino acid R282Q, the 
epothilone-resistance mutation. 
 
Growth inhibition effects of ixabepilone and laulimalide on PelA-resistance 
strains 
Paclitaxel is known to require five amino acid mutations before it can interact with 
the microtubules of yeast in vitro (Gupta et al. 2003); thus, it did not inhibit the 
proliferation of yeast at concentrations up to 150 µM, and it did not lead to G2/M 
block as detected by FACS analysis (Bode et al. 2002). According to Bode et al. 
(2002), epothilone B was also not effective in inhibiting yeast proliferation, possibly 
due either to metabolic transformation of the drug by the cells or inability of the drug 
to cross the yeast cell membrane. In the current study, aza-epothilone B (ixabepilone) 
was ineffective at concentrations up to 300 µM in various yeast strains including the 
drug efflux pump knockout strains (pdr5∆ and pdr1∆) (Fig. 2.3.13). Moreover, the 
addition of a cell membrane permeable agent SDS to the treated cells along with the 
drug did not aid in uptake of the drug i.e. there was still no inhibition of yeast 
proliferation. One should keep in mind that ixabepilone is a derivative of epothilone 
B, and the modification to its chemical structure makes it less toxic. The 
modification may also reduce its binding to isolated yeast tubulin, although this 
possibility has not been tested. Drug development certainly requires generating a 
number of analogs of drug candidates. Some of these analogs may have the same 
activity as the parent compound in a pharmacological assay but show reduced 
activity towards the tested organism in vivo. Others may show reduced activity 
toward the pharmacologically relevant target but similar activity towards the tested 
organism (Roberge, 2008). 
 
Preliminary screens with laulimalide showed that this drug was even more potent 
than PelA in the PelA-sensitive yeast strains (Fig. 2.3.10). More specifically, it was 
very potent in the pump knockout strains, shifting their growth curves to a lower µM 
concentration by almost 12-fold (Fig. 2.3.14). When this drug was tested against the 
site-directed point mutation strains, the results were similar to PelA, except for the 
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Arg282Gln mutation. This point mutation was initially included in this study as a 
negative control for PelA, but a positive control for epothilone derivatives, as it is an 
epothilone B-resistant point mutation in mammalian cells (Giannakakou et al. 2000). 
According to Giannakakou et al. (2000) amino acid Arg282 sits on the M loop in β-
tubulin. The M loop is believed to be important for lateral contacts between 
protofilaments and is located near the taxane binding site. However, since 
ixabepilone was not effective in yeast at concentrations up to 300 µM, no resistance 
could be measured. Nevertheless, this specific point mutation was semi-sensitive to 
laulimalide (Fig. 2.3.16) but not to PelA (Fig. 2.3.12), indicating that there might be 
some differences in the binding site between these two drugs. This is the first direct 
experimental evidence that PelA and laulimalide may bind differently to tubulin. 
Previous studies in mammalian cells by Gaitanos et al. (2004) showed that PelA and 
laulimalide bound to a similar or overlapping site on the microtubules, based on 
binding competition experiments. It is worthwhile to keep in mind that point 
mutations may change conditions globally in the molecule and as such, cause shifts 
in the ‘energy landscape’ since a resistance was also seen when an amino acid 
outside this site was altered, and this might reflect a global conformation change in 
the β-tubulin protein. They may also alter the distributions of the conformational sub-
states in a way similar to that of an external agent, such as temperature, pH, ionic 
strength, or pressure, or they may mimic a change in the binding conditions of a drug 
(Tsai et al. 1999; Kumar et al. 2000). Thus, effects of the mutations on drug 
sensitivities do not prove the amino acid involved is located at the binding site. 
 
Microtubule morphology changes  
Cell-cycle analysis of S. cerevisiae using bud index analysis showed specific cell 
morphologies at different stages of the cell cycle. The proportion of unbudded (G1), 
small budded (S), and large budded (G2/M) cells in the presence or absence of PelA 
was determined. As shown in Table. 2.3.4 and in comparison with untreated cells, 
more cells (2- fold) in the PelA-treated group were at the G2/M stage (34% large 
budded compared to 18% in the untreated sample), and fewer cells were in G1 or S 
and C phases of the cell cycle. The use of flow cytometry to monitor the cell cycle of 
individual cells in a population has been a standard tool for cell cycle studies in both 
mammalian cells and yeast cells. Flow cytometry analysis showed that after PelA 
treatment for 6 hr, a 3-fold increase in the proportion of cells in the G2/M stage was 
seen (53% in the treated sample compared to 16% in the untreated sample). A similar 
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effect was not seen with a longer PelA exposure of 18 hr. The early triggering of a 
reversible growth arrest may eventually lead to cell death with longer exposures. The 
short-term 6 hr exposure data are consistent with the bud index analysis. Together, 
these results suggest that treatment with PelA blocks cells at G2/M and prevents or 
slows further progression through the cell cycle. Cell cycle block supports the 
hypothesis that PelA binds and stabilises microtubules in yeast in a similar manner to 
that seen in mammalian cells (Hood et al. 2002). 
 
Observing yeast GFP-tubulin 
Other confirmation that PelA actually binds yeast tubulin comes from the yeast 
microtubule morphology changes seen upon addition of PelA in yeast with GFP-
tagged tubulin fusion protein. When PelA was added (Fig. 2.3.21), there was 3-fold 
(Table. 2.3.5) increase in the number of budded cells with long microtubule fibers or 
‘spindles’ shared between the mother and daughter cells. Thus, as with the cell cycle 
block results, PelA behaved in a similar way to mammalian cells, presumably 
binding to and stabilising polymerised microtubules. Finally, the other evidence that 
the PelA targets tubulin in yeast comes from the fact that mutations in the putative 
tubulin-binding site (Huzil et al. 2008; Snyder and Thepchatri, unpublished results) 
conferred resistance to PelA in both yeast and mammalian cells. 
 
In conclusion, we found that of the six point mutations generated, only Q291M failed 
to confer resistance in yeast. One of the mutations near the taxoid site (R282Q) that 
was not expected to confer resistance to PelA gave resistance to PelA but not to 
laulimalide. Overall, our data suggest that PelA binds to yeast tubulin in the region 
predicted by the published model of the binding site in mammalian cells (Huzil et al. 
2008) and that proposed by Snyder and Thepchatri (unpublished results). Our data 
support a binding site on β-tubulin rather than the α-tubulin site predicted by Pineda 
et al. (2004) and Jimenez-Barbero et al. (2006). Therefore, mapping the site on yeast 
tubulin could provide useful information about the mammalian binding site for PelA 
and laulimalide. This hypothesis is supported by the evolutionary conservation of 
sequence in these areas. Comparing PelA and laulimalide, a number of differences 
were seen. First, the two MSA had different IC50 values, with laulimalide being 10-
fold more potent in the pump knockout strains, equipotent in the haploid wild-type 
and 50% more potent in the haploid deletion mutant mad2∆. Second, there were 
different sensitivities to the R282Q mutation (the epothilone resistance site in 
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mammalian cells), and third, there was a greater effect of the efflux pump mutants on 
sensitivity to laulimalide. Hence, a single altered amino acid can affect PelA binding 
but not laulimalide binding, and vice versa, if their binding sites overlap but are not 
identical. Moreover, the definition of the PelA binding site needs to be considered in 
view of the evidence of unique binding interactions between purportedly similar drug 
that bind to the same site as PelA like laulimalide or any other drug that has the same 
effect as PelA on yeast microtubule. From our results using flow cytometry and bud 
index comparisons and the fact that mutations at a proposed tubulin-binding site 
confer resistance to PelA, we conclude that the PelA mode of action is similar to that 
in mammalian cells with regard to microtubule stabilisation leading to cell cycle 
arrest at G2/M.  
 
Future studies  
Additional experiments that could help to clarify the PelA and laulimalide mode of 
action in yeast would include in situ cellular tubulin polymerisation measurements by 
Western blotting (Hood et al. 2002) and tubulin immunocytochemistry to obtain 
better images of the effects of the drugs on the polymerised tubulin cytoskeleton. 
These studies had already been started, but due to the timeline of this project being 
limited, the studies were discontinued as a part of this thesis. Other future studies 
could continue with mapping the amino acids at, and outside, the PelA/laulimalide 
binding region in more detail to obtain unique binding profiles for the different 
MSA. Although paclitaxel and ixabepilone were not effective in yeast, a new MSA 
discovered recently with regard to its microtubule-stabilising activity, zampanolide 
(Field et al. 2009), may provide additional useful information on MSA interactions 
with specific amino acid residues on α- or β–tubulin. Experiments are currently in 
progress on determining the binding site of this new MSA. Preliminary experiments 
in yeast using zampanolide have revealed that the drug mode of action is similar to 
PelA in blocking cell cycle at G2/M (Natelle Quek, MSc student, Victoria University 
of Wellington, personal communication). It would be particularly useful if it was 
active in yeast and bound to the taxane site or even a totally unique site, since at 
present, none of the taxoid site drugs tested are effective in yeast. Finally, it would be 
helpful to take advantage of the ability to genetically manipulate yeast and use error-
prone PCR to generate a set of resistant yeast strains. The information from these 
strains could then be used to better understand PelA and laulimalide interactions and 
mechanisms that cells use to escape the action of these drugs. 
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Chapter 3. Finding the secondary targets of peloruside via chemical 
genetics microarray profiling analysis. 
 
3.1. Introduction 
3.1.1. Introduction to microarray 
In the past decade, the development of chemical genomic profiling (DNA 
microarray) technology has widely contributed towards the rapid progress in the 
research of genetic network analysis. Establishing genetic interaction profiling for a 
bioactive compound has become relatively easy especially in yeast due to the small 
genomic size of this organism. The yeast genome was fully sequenced in 1996 (SGD 
Stanford). By the year 2001, a deletion mutant strain for every gene in yeast was 
available (Giaever et al. 2002), and this particularly aided in the rapid progress of the 
field of genetic analysis of networks and provided a wide range of genomic tools.  
One of the most important genetic tools was the collection of yeast deletion mutants 
for nonessential genes (Winzeler et al. 1999). These deletion strains have led to a 
wide range of microarray data that have been collected from numerous studies, 
enhancing our understanding of many biological processes like gene expression 
during essential cellular processes such as in cell division (Simon et al. 2001; 
Spellman et al. 1998), meiosis and spore formation (Rabitsch et al. 2001), cellular 
responses to altered nutrient conditions (Gelling et al. 2004), and responses to a wide 
range of stresses and drug treatments (Gasch et al. 2000; Alic et al. 2004). 
 
The emergence of the new era of modern high-throughput genome-wide technologies 
like DNA microarray (and SGA) has revealed that a given function in our biological 
system is a result of multiple genetic interactions through networks and pathways. 
These networks or pathways of genes consist of modular units or nodes in which a 
group of genes commonly behave in the same manner across a set of experiments; 
therefore, these genes usually share a common cellular function (Bar-Joseph et al. 
2003). From these studies, it has turned out that co-expressed gene nodes are usually 
regulated by common transcriptional regulators or regulatory networks. 
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3.1.2. Introduction to homozygous deletion profiling (HOP) 
The yeast knockout (YKO) deletion mutants strains were created by homologous 
recombination in which each gene was deleted from start to stop codon and replaced 
with a kanamycin resistance (KanMX) cassette that carries the G418-resistance 
marker, which is required for the selection of transformants (Giaever et al. 2002).  
(Fig. 3.1.1). Specifically, the KanMX cassette is about 56 bp and is comprised of a 
unique 20 bp barcode ‘TAG’, flanked by shared (universal) primer sites for 
amplification by PCR, located immediately 5’ of every mutant strains. These primers 
are common to all strains and are used for the amplification of the barcodes from a 
pooled culture with changes in individual strain abundance measured simultaneously 
in a DNA microarray. In all but 192 knockouts, a second cassette with similar 
structure but a different pair of universal primer sites is situated immediately 3’ 
(Yuan et al. 2005).  
 
Figure. 3.1.1. Constructing yeast deletion mutant collection (YKO). This figure shows the KanMX 
deletion cassette flanked by the barcodes that are in turn flanked by four universal primer sites 
(coloured arrows) (figure adopted from Pierce et al. 2007). 
 
Approximately a complete set of yeast gene deletion mutants (96% of all open 
reading frames) is available for screening (Winzeler et al. 1999). In total 6000 genes 
have been deleted of which 1000 proved to be essential for growth; therefore, the 
gene deletion set consists of 5000 mutant strains (Giaever et al. 2002). Taking 
advantage of the unique barcode system, screening for the entire yeast gene deletion 
pool was made possible in a single experiment using chemical genomic profiling 
(microarray analysis). The DNA microarray contains complementary oligomers to 
the barcode sequences.  
 
HOP makes use of a set of deletion mutants in which every ORF has been 
individually replaced with an antibiotic resistance marker, either as a haploid or 
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homozygous diploid. The HOP assay can only be used for non-essential genes since 
a haploid mutation of an essential gene by definition will not grow (Armour and Lum 
2005). The HOP assay normally generates a larger number of genetic interactions, 
and these interactions are functionally connected to the target but are not the target 
itself “friends of the target”. In HOP, functional interactions between pathways 
targeted by the drug are revealed through the concept of synthetic lethality (Armour 
and Lum 2005). Synthetic lethality is a set of genetic enhancements (Hartman et al. 
2001) in which two mutations come together to cause a significant growth defect, 
though each mutation separately has an observable phenotype on its own (Fig. 3.1.2). 
A phenotypic characteristic is generally determined by more than a single gene 
product.  
 
Figure. 3.1.2. Haploid homozygous mutants are used in the HOP assay. The diploid wild type has 
two copies of gene A and B; their protein products interact with each other and lead to the same function. In the 
addition of the drug that interacts with gene A, and inhibits gene A protein transcription. Absence of gene A 
protein products can be compensated for by gene B); therefore, the cell remain viable in the addition of the drug. 
In the homozygous diploid, both copies of gene B are deleted, the addition of the drugs exerts a synthetic lethal 
(synthetic chemical genetics) effect on the cell by acting as a second mutation to create a non-viable double 
mutant. 
 
Yet, there are significant challenges facing the integration of large-scale analysis data 
sets of network, but the rapidly developing field suggests that this approach will be 
of enormous value in near future. As results of that, the wider emerging field of 
‘systems biology’ that we are approaching today, where the regulation and standards 
that underlines the genome-wide regulation of gene modules and the greater 
regulatory network, currently are well understood. This information has major 
implications for biological and medical research. 
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3.1.3. Aims of this chapter 
 
The aim of this chapter is to use the HOP microarray, which uses homozygous 
diploid deletion strains (BY4743), to deduce functional information about the 
mechanism by which small molecules interact with particular genetic interactions 
pathways i.e. to reveal synthetic lethal interactions among genes (or pathways) that 
are normally required to buffer cellular responses against the cytotoxic effects of a 
drug. Different deletion mutant strains will display sensitivity towards the drug (PelA 
in the present study) i.e. reduced growth. The HOP screen will give functional 
information about the deleted genes, identify the mechanism of action of the drug, 
and reveal functionally related or connected genes that buffer the yeast cell against 
the drug’s cytotoxic effect. The identification of the PelA-sensitive gene is made by 
noting the absence of the hybridisation signal (utilising the barcode identification 
system) in the drug-treated sample, thus revealing sensitivity of the corresponding 
deletion strain to the drug. Our hypothesis is that the HOP microarray will not 
identify the secondary targets of PelA but will link PelA to specific networks or 
biochemical pathways in the cells. 
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3.2. Materials and Methods 
 
3.2.1. Yeast competitive growth assay 
 
Preliminary experiments of yeast half-logarithmic growth inhibition curves of the 
haploid wild type strain (BY4741) were performed by Anja Wilmes during her PhD 
study at Victoria University of Wellington (Wilmes PhD thesis, 2008) to work out an 
optimal concentration of PelA for the microarray. Concentrations of drug that only 
affect the wild type cells to a minimum extent (IC10-IC20) are typically used for 
fitness profiling tests. The HOP microarray experiment was performed in duplicate 
(biological replicates were done one at a time) each time following a protocol 
provided by Dr. Rosemary Heathcote (ESR, Wellington) that was originally adopted 
from Yuan et al. (2004) and Parsons et al. (2006). A homozygous yeast knockout 
library pool (Invitrogen/Research Genetics Hom YKO pools) was stored at -80ºC at a 
cell concentration of 3.5 x 107 cells/0.5 mL. A 0.5 mL aliquot of this suspension was 
grown at 30ºC in 10 mL of synthetic complete (SC) medium (Appendix I) 
supplemented with 2% glucose, 25 mM HEPES and 0.1% G418 antibiotic 
(Geneticin, Gibco, Invitrogen). The cells were incubated overnight in a BioLane 
shaker incubator (Edwards Instrument Company, Australia). In order to ensure 1000-
fold coverage of each mutant, 5 x 106 cells were diluted into 10 mL SC medium 
containing 2% glucose and 25 mM HEPES in the presence of 10 µM PelA or a 0.1% 
DMSO control. After 15 hr (~10 generations), cells were re-diluted to 5 x 106 
cells/10 mL and re-treated with PelA or DMSO for an additional 15 hr (~20 
generations total). 
 
3.2.2. Genomic DNA purification.  
 
The Master PureTM yeast DNA purification kit (Epicentre Biotechnologies) was used 
following the manufacturer’s instructions, followed by RNA degradation by addition 
of 1 µL of RNase A (5 µg/µL) and incubation at 37ºC for 30 min. DNA was 
extracted by adding one volume of phenol/chloroform/isoamylalcohol (25:24:1), 
followed by vortexing and centrifuging at 16,000 g for 10 min. DNA was further 
purified by taking the upper aqueous phase and adding one volume of chloroform, 
followed by vortexing and centrifugation at 16,000 g for 10 min. The upper aqueous 
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phase was again transferred into a new tube, and the DNA was precipitated with 2.5 
volumes of ethanol (96%) and 1/10 volume 3 M Na acetate (pH 5.3). The samples 
were incubated at -20ºC for 25 min, followed by centrifugation at 16,000 g for 10 
min. The DNA was washed with 70% ethanol and redissolved in 35 µL TE buffer. 
DNA was quantified using Hoechst 33258 dye (1 mg/mL) (DNA Quantification kit 
DNA-QF, Sigma-Aldrich) following the manufacturer’s instructions. Fluorescence 
was measured in a SpectraMax plate reader (Molecular Dynamics, Sunnyvale, CA) 
at 360 nm excitation and 460 nm emission wavelengths. A typical DNA 
concentration of 300 ng/5 µL was obtained. DNA aliquots were adjusted to 25 
ng/µL. 
 
3.2.3. Barcode amplification and Cy3/Cy5-dye labelling by PCR 
 
PCR Master Mix was prepared in a DNA-free laminar flow hood. The composition 
of PCR Master Mix is given in Table 3.2.1. Four PCR reactions are required for each 
experiment. Up and Down tags were amplified in separate reactions for both the 
control and experimental DNA samples. DMSO-treated controls were labelled with 
primers containing Cy3, two reactions were prepared for control sample: the first 
reaction used UP tag PCR primers (Primers U1 and U2comp-Cy3), and the second 
one used DOWN tag PCR (Primers D1 and D2comp-Cy3) primers. PelA-treated 
samples were labelled with primers containing Cy5 using UP tag PCR primers 
(Primers U1 and U2comp-Cy5) in one reaction and DOWN tag PCR primers 
(Primers D1 and D2comp-Cy5) in the second reaction (see Table 3.2.2 for primer 
sequences). Negative controls for each reaction were included (dH2O instead of 
DNA). In each PCR tube, 51.2 µL of PCR Master Mix was mixed with 2.4 µL 
labelled primer (25 µM stock) and 2.4 µL unlabelled primer (25 µM stock). Final 
concentrations of primers were 1 µM. To all reactions, 4 µL of 25 ng/µL DNA was 
added, except for negative controls in which dH2O was added instead. The final 
volume of each PCR reaction was 60 µL. PCR was carried out on a T-Gradient PCR 
machine (Biometra®) with PCR settings as follows: 94°C 3 min, 94°C 30 sec, 50°C 
30 sec, 72°C 30 sec for 38 cycles, 72°C 5 min and pause at 10°C. Following PCR, 5 
µL of each PCR product was run on a 4% MetaPhor agarose gel for 1 h at 100 V. 
The size of the amplified products for UP and DOWN tags was 56 bp. Tubes 
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containing PCR products were wrapped in foil and stored at -20ºC (if hybridisation 
was not performed on the same day). 
 
Table.3.2.1. PCR Master Mix 
 
Reagent                   Volume in µL for 1x* reaction          Final concentration  
 
10 x Platinum taq buffer   6     1x 
50 mM MgCl2    1.8    1.5 mM 
dNTPs (10 mM each)   1.2     0.2 mM 
Platinum taq (5 U/µL)   0.2     1U 
dH2O      42     - 
 
Total Volume    60µL 
 
*
 Reaction mixture for a single PCR reaction (9x master mix was prepared for one array). 
 
 
 
Table. 3.2.2. Primer sequences for yeast microarray 
 
Primer name      Primer sequence 
 
Down1      5'-CGGTGTCGGTCTCGTAG 
Up1       5'-GATGTCCACGAGGTCTCT 
Down2 labelled Cy3 or Cy5    5'-Cy[3/5]-CGAGCTCGAATTCATCGAT 
Up2 labelled Cy3 or Cy5  5'-Cy[3/5]-GTCGACCTGCAGCGTACG 
 
 
PCR settings for yeast microarray 
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3.2.4. Microarray hybridisation.  
The PCRs from Cy3-treated control and Cy5-drug-treated were hybridised onto the 
slide together for the duplicate microarrays (independent biological replicates done 
separately) (Yuan et al. 2005). Hybridisation mixture was prepared by adding 50 µL 
of each of the 4 PCR products, and 20 µL blocking solution (100 µM U1, 100 µM 
D1, 100 µM U2 block [5'-CGTACGCTGCAGGTCGAC], 100 µM D2 block [5'- 
ATCGATGAATTCGAGCTCG]). Both blocking solution and 2x hybridisation 
buffer were filter-sterilised and stored at 4ºC. DTT was added to 2x hybridisation 
buffer to a final concentration of 1 mM to prevent Cy-dye oxidation. The 
hybridisation mixture was denatured at 95ºC for 2 min followed by cooling on ice. A 
microarray chamber was set up according to the Agilent microarray-hybridisation 
chamber user guide. The microarray slide is designed with four arrays, with 44,000 
spots per array (Agilent), and 150 artificial tags as negative controls with tags 
replicated at least twice (Yuan et al. 2005). The microarray chamber was placed into 
a preheated (42ºC) hybridisation oven (Agilent technologies, Sheldon manufacturer, 
USA) at a rotation speed setting of 4 for 4 hr. The microarray slide was separated 
from the gasket slide in 300 mL of 6x SSPE washing solution (3 M NaCl, 0.2 M 
NaH2PO4, 20 mM EDTA, pH 7.4). The microarray slide was then transferred quickly 
to 50 mL of 0.06x SSPE washing solution. Both wash solutions were filter-sterilised 
before use. The slide was then removed from the washing solution and centrifuged at 
RT for 2 min at 500 rpm in a 50 mL Falcon tube with Cy-label at the bottom of the 
tube. The slides were then air-dried overnight and stored in the dark. Microarray 
slides were scanned with an Axon Microarray Scanner at the Otago Genomics 
Facility, Biochemisty Department, University of Otago, Dunedin, New Zealand. 
Scanning settings were 532 nm laser intensity for Cy-3 fluorescence i.e. DMSO-
treated (control) sample, and 635 nm laser intensity for Cy-5 i.e. PelA-treated 
samples. 
 
3.2.5. Microarray analysis  
 
GenePix Pro 6.0 (Molecular Devices, Sunnyvale, CA, USA) was used for the 
analysis of the microarray hybridisation fluorescence pattern. Control and essential 
genes were filtered out i.e. removed. Signals for UP Tags were analysed separately 
from DOWN Tags. Only spots that had a signal that was at least 3x higher than the 
background were used to calculate a median of ratios (Cy5/Cy3). The median of 
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ratios was then converted into a log2 ratio and normalised using SNOMAD web-
based software (Standardization and Normalization of Microarray Data). Genes 
ratios with less than 500 in the Cy-3 fluorescence (control sample) were filtered out 
(not included in the analysis). Replicates were removed using a ‘remove replicates’ 
program designed by Cameron Jack (School of Biological Sciences, Victoria 
University of Wellington). The values of log2 ratio for each hit were averaged, and 
the mean and standard deviation of the log2 ratio was calculated. Finally, z-scores 
were calculated using the following equation: Z-score = (x-mean)/standard deviation. 
Values for all UP (or DOWN) tags were used for calculation of mean and Std. 
deviation. Z-scores greater than three Std. deviations were considered significant and 
defined as a ‘hit’. Multidrug resistance (MDR) genes were filtered out from the final 
hit list using the Hillenmeyer-HOP-MDR list (Hillenmeyer et al. 2008)  
 
3.2.6. Database searches 
 
SGD Gene Ontology Slim Mapper web-based maps (SGD Stanford) were used to 
annotate/classify a group of genes to more general groups and/or bin them into broad 
categories or networks. Moreover, to classify ORF genes based on their molecular 
function, “Cellular Component” and biological function of the ORF were subjected 
to FunSpec, a web-based software program that groups genes into their listed 
categories. Physical and genetic interactions of genes/proteins were searched with the 
“interactions” tool on the Saccharomyces Genome database (SGD Stanford). Using 
Cytoscape software (v2.6.2) downloaded via the http://www.cytoscape.org/ website, 
genes were grouped into their biological processes using BiNGO implemented 
plugins (A Biological Network Gene Ontology tool). BiNGO is a Java-based tool to 
determine which Gene Ontology (GO) categories are statistically overrepresented in 
a set of genes or a subgraph of a biological network. 
 
3.2.7. Validation of HOP results: Growth inhibition experiment 
 
To validate the HOP microarray hits (that is, to confirm the genes with Z-scores 
greater than three standard deviations), homozygous deletion mutants strains were 
obtained from -80ºC stocks and streaked onto plates as previously stated in section 
2.2.1. A single colony from each strain was inoculated in 2 mL SC supplemented 
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with 2% glucose and grown overnight at 30°C in a rotator. The diploid wild type 
strain (BY4743) was included as a positive control. The following day, the 
concentrations of the cultures were determined using a haemocytometer, and the 
cells were diluted in 10 mL SC medium  to a final cell concentration of 5 x 105 
cells/mL. Then, 100 µL of the diluted cells were plated out in BIOFIL® tissue culture 
96-well plates, giving 5 x 104 cells per well final concentration. Cells were treated 
with 10 µM PelA or 0.1% DMSO (control) for 15 hr (~10 generations) and were 
incubated at 30ºC in a Contherm Digital series incubator (Contherm Z011, Contherm 
Scientific Ltd, New Zealand). Following this incubation, the cells were re-diluted in 
order to have a minimum of 1000 cells per well (the same procedure was followed as 
in the yeast microarray set up- refer to section 3.2.1) and were re-treated with 10 µM 
PelA or DMSO for an additional 15 hr (~20 generations total). Plates were vortexed 
at 1000 rpm for 15 sec to resuspend the culture and the absorbance of the plates was 
read at 600 nm wavelength on a multilabel plate reader (PerkinElmer EnVision 2102, 
Waltham, Massachusetts, USA), and the residual growth for each gene was 
calculated relative to its positive control (DMSO-treated). As this validation 
technique utilises substantial amounts of PelA, and since the drug was only available 
in limited supply, this experiment was not repeated. 
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3.3. Results 
3.3.1. HOP microarray hits 
 
Using the complete homozygous (BY4743) deletion mutant library for S. cerevisiae, 
a microarray screen was carried out against PelA in order to reveal functional related 
pathways or genes that interact with PelA primary targets. Mutants scoring greater 
than three z-score were considered as significant hits for this HOP microarray after 
10 µM treatment with PelA for 20 generations (Table 3.3.1). Thirty-three genes had 
z-scores of 3 or higher in at least one of the two HOP microarray screens. Eight of 
these genes were component genes of the PDR multidrug efflux system and therefore 
were not followed up further since they would not provide information on the 
specific action of PelA. Twenty-five strains (z-scores above 3) were significant in 
both microarrays, and these strains were validated individually (see Materials and 
Methods). ERG24 and ERG6 were excluded from the validation results because cells 
lacking these genes exhibit pleiotropic growth phenotypes (Gaber et al. 1989). Five 
strains showed significant z-scores for both the UP and DOWN tags (in both 
biological replicates of the microarray). Those strains were RTS1, SAC1, MAD1, 
MAD2 and LSM1. These results were consistent between experiments. In both 
microarray screens the log2 ratios and the z-scores of the hits were highly significant. 
The SGD Gene Ontology search that was performed using Funspec grouped the 
genes into eight major categories (Table 3.3.2) with mitosis being the most relevant 
category for what is known about the mode of action of PelA (Hood et al. 2002). 
Individual validation of each hit using growth inhibition experiments validated 10 
out of 23 genes as sensitive to PelA-treatment, indicating that those genes reflect the 
possible “friends of PelA targets”. The percentage of growth for each gene is 
presented in Table 3.3.3. The possible PelA genetic interactions are presented in the 
network shown in Fig. 3.3.1. The functions of the HOP gene hits are summarised in 
Appendix V.  
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Table. 3.3.1. Microarray hits after 10 µM PelA treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The BY4743 homozygous deletion mutant set was treated for 20 generations with 10 µM PelA. 
Thirty-three gene deletion mutants strains returned z-scores of 3 or greater in two experiments. Genes 
in bold are multi-drug resistance genes and were removed from the final hit list. Based on 2 biological 
replicates with arrays carried out in duplicate for each preparation (the log2 ratios and z-score values 
shown here were obtained from averaging the results of the two biological replicates). An example on 
the log2 ratio and the z-scores values (from the two biological replicate) is shown below: 
    replica one         replica two 
   log2 ratio  z-score  log2 ratio  z-score 
LEM3    -6.95  -17.0  -5.45  -14.46 
 
 
 
 
 
 
 
 
Strain 
 
Gene name Median of ratios 
(Cy5/Cy3) 
Log2 ratio z-score 
 
YNL323W LEM3 0.003 -6.21 -15.74 
YNL280C ERG24 0.069 
-4.47 -11.22 
YCL029C BIK1 0.019 -3.88 -9.81 
YOR014W RTS1 0.037 -3.32 -8.42 
YBR189W RPS9B 0.032 -3.27 -8.08 
YKL212W SAC1 0.049 -3.40 -8.07 
YBL065W - 0.017 -3.16 -7.60 
YML008C ERG6 0.021 -2.95 -7.30 
YOR153W PDR5 0.047 -2.63 -6.69 
YPL187W MF(ALPHA)1 0.068 -2.51 -6.07 
YGL086W MAD1 0.043 -2.38 -5.90 
YJL030W MAD2 0.06 -2.31 -5.64 
YDL115C IWR1 0.116 -2.33 -5.60 
YNL054W VAC7 0.141 -2.12 -5.27 
YNL187W - 0.075 
-2.06 -4.92 
YDR264C AKR1 0.099 
-1.90 -4.83 
YPL018W CTF19 0.149 
-2.02 -4.81 
YOR292C YOR292C 0.065 -1.86 -4.71 
YBR156C SLI15 0.089 -1.92 -4.59 
YBL054W - 0.164 -1.66 -4.14 
YDR441C APT2 0.094 -1.74 -4.13 
YER087W AIM10 0.176 
-1.71 -4.11 
YJL124C LSM1 0.176 
-1.62 -4.01 
YGL012W ERG4 0.093 
-1.62 -3.98 
YGL170C SPO74 0.165 
-1.56 -3.93 
YLR085C ARP6 0.082 
-1.55 -3.92 
YHR025W THR1 0.163 
-1.50 -3.79 
YOR019W - 0.102 
-1.46 -3.67 
YGR106C - 0.234 
-1.47 -3.54 
YOR161C PNS1 0.106 
-1.45 -3.51 
YMR202W ERG2 0.098 
-1.38 -3.32 
YIL157C COA1 0.122 
-1.35 -3.23 
YDR017C KCS1  -1.22 -3.10 
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Table. 3.3.2. Funspec Gene ontology by biological process-Pel A 
 
The Funspec gene ontology classified the genes into their biological processes. The p-values represent 
the probability that the intersection of a given list with any given functional category occurs by 
chance. The Bonferroni-correction divides the p-value threshold that would be considered significant 
for an individual test, by the number of tests conducted and thus accounts for false significance due to 
multiple testing over the categories of a database. 
 
 
 
 
 
 
 
 
 
 
 
Category p-value Genes in 
category from 
cluster 
Mitosis  0.001642 BIK1 MAD1 
MAD2 CTF19 
Meiotic sister chromatid cohesion, centromeric  0.003786 RTS1 
RNA splicing, via transesterification reactions  0.003786 LSM1 
Steroid biosynthetic process  0.004231 ERG6 ERG24 
Ergosterol biosynthetic process  0.004898 ERG6 ERG24 
Mating  0.007559 MF(ALPHA)1 
Prolyl-tRNA aminoacylation  0.007559 AIM10 
RNA splicing, via transesterification reactions with 
bulged adenosine as nucleophile  
0.007559 LSM1 
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Figure. 3.3.1. PelA-HOP genetic interactions network  
 
 
 
The PelA-HOP network is presented. Hits were obtained from the microarray analysis. The network was 
constructed by Cytoscape 2.6.1 software, and p-values were calculated using the BiNGO 2.3. plugin that is 
implemented within the cytoscape software. 
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Table.3.3.3. Individual validation of HOP-microarray hits. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Twenty-three homozygous deletion mutant strains were treated individually with 10 µM PelA or 
DMSO (as control) for up to 20 generations. Percentage of residual growth was calculated relative to 
DMSO-treated (control) samples for 15 hr (10 generations) incubation and 30 hr total growth (20 
generations). Only 10 genes (in bold) out 23 genes showed a significant decrease in their growth after 
20 generations (Residual growth of less than 80% of the control was considered a significant effect). 
Results are ranked according to percentage growth after 20 generations. Results are based on only one 
experiment due to the limited supply of the drug; hence, no statistical analysis could be performed. 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Name  10 gen. 20 gen. 
KCS1 86% 26% 
MAD1 65% 30% 
BIK1 77% 31% 
RTS1 71% 33% 
LSM1 92% 36% 
SAC1 62% 42% 
CTF19 81% 45% 
MAD2 85% 49% 
RPS9B 99% 71% 
VAC7 77% 73% 
YBL054W 104% 78% 
MF(ALPHA)1 95% 79% 
PNS1 101% 82% 
YOR019W 103% 87% 
COA1 94% 88% 
APT2 98% 89% 
YNL187W 104% 93% 
YOR292C 102% 94% 
AKR1 89% 96% 
AIM10 104% 97% 
IWR1 98% 98% 
SPO74 99% 104% 
YBL065W 105% 110% 
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3.4. Discussion 
 
Chemical genomic profiling of PelA 
Chemical-genetic profiles (HIP and HOP microarrays) screen for primary and 
secondary biological targets, have the potential of revealing the mode-of-action of 
the drugs being tested. Technically HIP and HOP microarrays each follow the same 
methodology; however, in a HOP screen, nothing can be learnt about the drug targets 
since only homozygous deletion mutants are used in this screen and these strains are 
characterised by complete loss of function of the deleted gene in the mutants. HOP 
microarrays therefore only find friends of the target, rather than the target itself, but 
HOP microarrays are important because they reveal genes that are important for the 
survival of the yeast in the presence of a drug (Nislow and Giaever, 2007), and 
therefore identify functionally related pathways of the drug of interest (genes that 
associate with the drug target). Barcode-based chemical genomic profiling in 
budding yeast is relatively straightforward and robust and can be generally applied to 
any compound with growth inhibitory activity (Parsons et al. 2006).  
 
In contrast to chemical genomic profiling of haploid deletion mutants like SGA, 
which often identifies tens to hundreds of deletion mutant hypersensitive strains, the 
microarray (HIP and HOP) usually identifies a reasonably manageable number of 
potential drug target genes (HIP) or genes that associate with the drug target (HOP). 
Microarray genome-wide screens often identify fewer than 20 genes per screen, in 
which gene deletion leads to compound hypersensitivity (Baetz et al. 2004; Giaever 
et al. 1999, Giaever et al. 2004; Lum et al. 2004). Hence, the HOP assay is a 
powerful complement to the HIP assay as it allows the identification of genes and 
pathways required for protection of the cell from inhibition of a particular target. 
However, in some cases the HOP microarray technique generates discrepancies in 
the data within and between independent experiments (replicates), and therefore, 
because of lack of consistency, a substantial number of hits (genes) must be excluded 
from the analysis. In this case, HOP screens are incomplete because they do not 
highlight some genes that might play an important role in the drug pathway. This 
often results from a problem with the PCR efficiency of Up and DN tags 
(collectively or separately) in which some strains have a low DNA (template) 
quantity to start with. In the present study, the results were relatively consistent 
between experiments. In both microarray screens, the log2 ratios and the z-scores of 
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the hits were highly significant, and few genes were excluded from the analysis 
because they only showed up as hits in one of the two replicates.  
 
PelA HOP microarray hits 
The HOP microarray analysis for the complete homozygous diploid (BY4743) strain 
treated with 10 µM PelA for 20 generations disclosed 23 genes with z-scores greater 
than three. The Go Biological Process grouped these genes according to their 
biological process into eight categories.  
 
In the first category, the BIK1, MAD1, MAD2 and CTF19 genes were grouped into 
the mitosis group. Synthetic lethal studies by others have revealed that α- and β-
tubulin have genetic interactions with BIK1 (Berlin et al. 1990). This gene seems to 
be required for nuclear fusion, chromosome disjunction, and nuclear segregation 
during mitosis and the protein product of BIK1 co-localises with tubulin to the 
spindle pole body and mitotic spindle (Berlin et al. 1990). The strain that is a double 
mutant containing a mutation in the BIK1 gene and either the α- or β-tubulin gene is 
synthetic lethal. The synthetic lethal findings are consistent with what has been 
observed from direct physical interactions between this BIK1 and tubulin (Berlin et 
al. 1990). Validation of the homozygous deletion diploid strain that lacks BIK1 
showed that this strain was sensitive to PelA treatment, with only 31% growth (69% 
inhibition) in the presence of PelA (Table. 3.3.3.).   
 
Besides BIK1, MAD1 and MAD2 were also present in the same mitosis group. The 
mad mutants were initially isolated in a study that used benomyl, an inhibitor of 
microtubule polymerisation. These mutants showed increased sensitivity when 
treated with the drug (Hardwick et al. 1999), failing to arrest in mitosis, and dying 
rapidly (Li and Murray, 1991; Hardwick and Murray, 1995; Hardwick et al. 1999). 
These observations suggest that the defects in microtubule polymerisation have 
activated the spindle checkpoint (Hardwick et al. 1999). Previous studies between 
mad mutants and β-tubulin have shown that the combination of the mad mutations 
with the tub2 mutation increases the rate at which cells, which cannot polymerise 
microtubules, and die (Hardwick et al. 1999). The outcome of these observations 
demonstrated that the MAD-dependent spindle checkpoint is essential to arrest cells 
that have a defect in microtubule assembly (Hardwick et al. 1999). The MAD1 and 
MAD2 are non-essential genes that encode components of the spindle checkpoint (Li 
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and Murray 1991; Hardwick and Murray 1995). MAD2 forms a tight complex with 
MAD1 throughout the cell cycle. In the present study, the HOP growth inhibition 
assay confirmed that both mad1∆ (30% growth) and mad2∆ (49% growth) strains 
were quite sensitive to 10 µM PelA. This sensitivity of a mad2∆ strain confirms 
earlier studies by Anja Wilmes who showed that PelA sensitivity was increased in 
this strain over wild type (Wilmes PhD thesis, 2008). In a HIP microarray study 
carried out in our laboratory by Anja Wilmes (Wilmes PhD thesis, 2008), CIK1, a 
kinesin-associated protein required for both karyogamy and mitotic spindle 
organisation (SGD Stanford), was identified as one of the hits and potential targets of 
PelA. CIK1 also has been shown to have a synthetic lethal interaction with MAD1and 
MAD2 (Daniel et al. 2006; Collins et al. 2007; Sarin et al. 2004). Nevertheless, the 
mad mutants came as a hit in the HOP microarray screen and when both mutant 
strains were individually treated with 10 µM PelA for 20 generations, they showed 
30-49% growth i.e. 51-70% inhibition (Table. 3.3.3). Besides the genes listed above, 
CTF19 was also included in the mitosis group. This gene codes for an outer 
kinetochore protein, and individual growth validation of the homozygous diploid 
strain that lacks this gene showed that this strain had only 45% growth (55% 
inhibition) in the presence of 10 µM of PelA after 20 generations (Table. 3.3.3). 
 
The second Go Biological Process category consisted of a single gene (RTS1) that is 
involved in sister chromatid cohesion and is a B-type regulatory subunit of protein 
phosphatase 2A (SGD Stanford). This gene rts1 was identified as an extragenic 
suppressor of tub2-104. Tub2-104 is a cold-sensitive allele of the gene encoding β-
tubulin in S. cerevisiae (Reijo et al. 1993). Individual growth validation of the 
homozygous diploid strain that lacks this gene showed that this strain had only 33% 
growth (67% inhibition) in the presence of 10 µM of PelA after 20 generations 
(Table. 3.3.3). CIK1, one of the HIP microarray hits as mentioned earlier (Wilmes 
PhD thesis, 2008), has a phenotypic enhancement type of genetic interaction with 
LSM1 and RTS1 (Collins et al. 2007). Phenotypic enhancement is a genetic 
interaction that is inferred when mutation or overexpression of one-gene results in 
enhancement of any phenotype (other than a lethality/growth defect) associated with 
mutation or overexpression of another gene (SGD Stanford). Our validations showed 
that gene LSM1, which belongs to the third Go Biological Process category (the 
RNA splicing group) and is involved in sister chromatid cohesion (SGD Standford), 
had only 36% growth (64% inhibition). Another gene was also picked up in the HIP 
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microarray hits of Anja Wilmes, TOP1 (Topoisomerase I) that functions in 
replication, transcription, and recombination (SGD Stanford), and was also shown to 
have a phenotypic enhancement genetic interaction with LSM1 (Collins et al. 2007; 
Fiedler et al. 2009). Overlaps between other genes found in this study and the HIP 
study were not found.  
 
The other Go Biological Process categories involved steroid or ergosterol 
biosynthesis, including ERG6 and ERG24, two genes are involved in multidrug 
resistance and were eliminated from the validation list. Of the twenty-three identified 
genes, seven had no known function, including IWR1, YNL187W, YOR019W, PNS1, 
YBL065W, APT2 and YOR292C.  
 
Validation of HOP microarray results by individual strain confirmation 
Validation of the HOP microarray hits is quite important, because it will confirm the 
results by using independent measurements. The validation of the strains that are 
identified in genome-wide assays need to be carried out in individual liquid cultures 
before the results are considered complete. When the HOP hits were individually 
validated by growth inhibition assay, 10 out of the 23 genes were very sensitive to 10 
µM PelA after 20 generations (less than 80% of residual growth). Those genes were 
SAC1, MAD1, MAD2, LSM1, RTS1, CTF19, BIK1, KCS1, RPS9B and VAC7 with 
growth inhibition values for PelA ranging from 26% to 73% after 20 generations 
(Table. 3.3.3). Some of these genes have been discussed in more detail earlier            
(BIK1, MAD1, MAD2, LSM1, RTS1, and CTF19); therefore, they will not be 
mentioned in this part of the discussion. SAC1 is a transmembrane protein involved 
in trafficking, processing, and secretion, as well as cell wall maintenance (SGD 
Stanford). This strain had 42% growth relative to the control (i.e. 58% inhibition) in 
response to 10 µM PelA after 20 generations. The human homologue to SAC1 is 
human Sac1 (hSac1), a member of a family of phosphatases that are involved in 
protein trafficking and processing (SGD Stanford). The other three strains whose 
growth was also decreased after 20 generations were KCS1 (26%), RSP9B (71%) and 
VAC7 (73%). These genes are involved in DNA repair, and vacuolar biogenesis 
respectively (Appendix V).  
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Other techniques that can reveal functionally related genes 
 
Parsons et al. (2004) employed the SGA method to uncover cellular pathways 
affected by various compounds in yeast (Parson et al. 2004). In preliminary studies, 
the authors treated the haploid yeast deletion collection with twelve diverse 
inhibitory compounds to create chemical-genetic interaction profiles for each drug. 
Strains that showed hypersensitivity towards a specific compound were identified by 
arraying the strains onto agar plates containing a sub-lethal dose of each compound 
and looking for reduced colony formation. The SGA technique concepts are similar 
to the HOP microarray. The only difference between the two is that SGA is carried 
out on a solid phase; whereas, HOP is carried out in a small liquid volume or ‘pool’ 
(Pan et al. 2004). These studies identified 35 new synthetic genetic interactions for 
the 12 drugs. Comparing the data that have been collected from various chemical-
genetic screens with a compendium of fifty-seven genetic interaction screens of 
query genes indicated that the genetic interaction profile of many query genes 
clustered with the chemical-genetic profile of the drug affecting them. For example, 
the profile of TUB2 and MAD2 in the Parson et al. (2004) study clustered with the 
profile of benomyl (the microtubule-depolymerising drug). Thus, these genetic 
interaction profiles can provide useful information for interpreting chemical-genetic 
interaction profiles and therefore can identify the cellular targets or pathways of 
compounds (Parsons et al. 2004). 
 
In a modification of the SGA method, Pan et al. (2004) developed a microarray-
based technique called dSLAM (diploid based synthetic lethality analysis with 
microarrays) to generate haploid mutants for probing gene-chemical and gene-gene 
interactions (Parsons et al. 2006). In this modified version of SGA, into a pool of 
5,896 heterozygous diploid deletion strains were used to generate haploid-
convertible heterozygous diploids via the integration of SGA reporters. These 
haploids were generated after sporulation and selection on appropriate media. In 
order to test the resistance of the converted haploids, they were treated with benomyl, 
a microtubule depolymerising drug that is known to affect 78 non-essential genes 
(Parsons et al. 2006), to test for their resistance. The haploid pool was grown with 
and without the drug, and the DNA was isolated, amplified and subsequently 
hybridised to an oligonucleotide array of sequences complementary to the molecular 
barcodes of each strain (Winzeler et al. 1999; Baudin et al. 1993). The microarray 
barcode analysis showed that the mutant strains for genes that are directly involved 
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in microtubule biogenesis knocked out, such as CIN1, TUB3, and PAC10, were 
hypersensitive to benomyl treatment (Parsons et al. 2004; Pan et al. 2004). 
 
In conclusion, the HOP results in our study indicated that the PelA genetic 
interactions are genes mainly involved in the regulation of mitosis and cell cycle, 
protein transport and secretion, and steroid biosynthesis pathways. Thus, genes in 
these pathaways buffer the cellular response against the PelA effect and, when 
mutated, increase the growth inhibitory effects of PelA. The individual validation 
assay data largely confirmed what was seen in the HOP microarray experiments. 
However, the results of the validation experiments should be repeated as each strain 
was done only once because the PelA supply was limited. To confirm these results 
another technique needs to be carried out as well e.g. SGA that uses PelA to identify 
strains that are synthetically lethal in the presence of the drug. It would also be useful 
to apply the drug in excess to validate the HOP hits.  
 
The advantage of microarray analysis is that this technique is comprehensive and 
examines the involvement of nearly every non-essential nuclear protein-encoding 
gene in a drug response. The technique is therefore unbiased since it does not make 
assumptions about the drug’s mechanism of action, as would be the case if selected 
genes were investigated. In general, the technique is applicable to any compound that 
is bioactive and inhibits yeast growth (Parsons et al. 2006). It is also technically easy 
and inexpensive, other than the cost of the drug itself. It helps in reducing the number 
of potential targets, although it might be difficult to disentangle the primary targets 
from the secondary targets. The disadvantage of a HOP microarray screen in 
particular is that a substantial fraction of the homozygous diploid deletion strains 
might be slow-growth strains in the absence of a drug. This can lead to uninformative 
screen results as these strains become gradually depleted in the pool and therefore 
give false positives. Sometimes, a HOP microarray may identify what appear to be 
secondary targets that are completely unrelated to (or associated with) the primary 
drug target(s), or it may identifies genes that are only relevant to yeast and have no 
mammalian counterpart. Despite these disadvantages, microarray analyses (HIP and 
HOP) will remain an attractive and alternative approach for many laboratories. 
 
 
 
- 81 - 
 
Chapter 4. Overall discussion and future experiments 
 
4.1. Discussion and conclusions from the study 
 
Many essential cellular processes are conserved between yeast and humans. About 
20 percent of human disease genes have counterparts in yeast. This means that yeast 
can be exploited to look at functional relationships involving these genes, and to test 
new drugs for their mode of action. A yeast mutant that has lost the functional 
equivalent of a human disease gene can be screened with thousands of potential 
drugs in order to identify compounds that restore normal function to the yeast cell.  
 
The generation of mutants via the use of mutagenesis is a useful element of any drug 
discovery study for determining interactions between the drug and its target. 
Understanding the drug and target protein relationship is potentially informative as it 
underlines the principles behind protein structure-function relationships. Mutant 
generation is a valuable tool in discovering the connection between a drug and its 
protein target since a change in an amino acid can disrupt the three-dimensional 
conformation of a protein and provide information about the functional pathways that 
this protein acts in. There are different forms of mutagenesis. Classically mutants are 
generated by treating the organism with mutagens (chemical or physical agents) that 
modify the DNA. This method is an extremely successful mutagenesis method, but 
suffers from a number of disadvantages. For example, any gene in the organism can 
be mutated, and the mutation that has occurred might not be in the gene of interest. 
However, a more direct approach is to change a selected base in a DNA sequence by 
site-directed mutagenesis and thus alter a particular amino acid that you suspect is in 
the binding site of the drug. Since the discovery of this technique, it has become a 
basic tool of gene manipulation and has simplified the manipulations of DNA that in 
the past required a great deal of ingenuity and hard work. The importance of site-
directed mutagenesis goes beyond the understanding of gene structure-function 
relationships. This technique enables mutant proteins with valuable novel properties 
to be created.  Generating PelA-resistance mutants is one of the effective ways to 
provide support for the hypothesis that the main target of PelA is β- not α-tubulin. In 
the presence of the drug, generated mutants in the β-tubulin binding site region were 
completely resistant to PelA. If PelA does not bind to the site on β-tubulin where the 
- 82 - 
 
mutated amino acid resides, then the only other explanation for resistance is that the 
three-dimensional structure of the protein was disrupted; therefore, its function was 
disrupted in a non-specific, global sense. The proof that the Huzil et al. (2008) model 
of the PelA binding site is correct requires the analysis of mutants that have amino 
acid changes at key residues. The PelA mutants could also be tested against some 
other drugs that target the microtubule, but bind to a different, perhaps better-
characterised site. In our study, phenotypic and quantitative analysis of the yeast cell 
cycle proved to be effective and informative about the mode of action of PelA, 
showing that its mode of action in yeast was similar to that in mammalian cell lines, 
with a G2/M block in the cell cycle.  
 
Drug discovery usually faces a major challenge to identify the cellular targets that are 
responsible for the activity of a drug candidate. Drugs rarely or perhaps never target 
only one gene. The primary goal of chemical-genomic profiling studies like 
microarray is to identify pharmacologically relevant primary and secondary drug 
targets (Roberge, 2008). The primary target of PelA is well established as the 
microtubule that has a major and essential role in mitosis. The PelA chemical genetic 
interaction profile in our study confirmed an activity associated with the cell cycle, 
but also suggested a potential activity in protein transport, secretion, cell wall 
synthesis, and steroid biosynthesis. It is not known for certain, however, whether 
these other responses are downstream effects from the primary target or independent 
secondary target effects.  
 
The overall conclusion from our study is that peloruside interacts with yeast tubulin, 
more specifically β- not α- tubulin. Our results indicated that PelA binds to the site 
proposed by Huzil et al. (2008) on tubulin, since site-directed mutation in specific β-
tubulin residues at this site-conferred resistance to PelA. Some resistance was also 
seen when an amino acid outside this site was altered, and this might reflect a global 
conformation change in the β-tubulin protein. Further site-directed mutagenesis 
studies are needed to clarify these possibilities. For example, it would be interesting 
to see if a mutation in α-tubulin could also confer resistance to PelA, especially since 
an α-tubulin binding site has been proposed by others (Pineda et al. 2004; Jimenez-
Barbero et al. 2006). The PelA mode of action in yeast appeared to be similar to that 
of mammalian cell lines i.e. G2/M block. Furthermore, its secondary targets or 
downstream pathways of action were mostly involved in the cell cycle, indicating 
that peloruside targets genes or gene networks that primarily act in cell cycling. This 
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conclusion is consistent with the known action of PelA on the microtubule and its 
major role in cell mitosis. 
4.2. Future experiments 
 
Confirmation of the PelA binding site in yeast is a very important task as it is 
difficult to use mammalian cells for generating mutations that confer resistance. A 
resistant yeast cell line would be easier and faster to generate. PelA-resistant cells 
that carry mutations in the tubulin gene may provide valuable information for 
modelling studies of PelA-tubulin interactions and for defining the PelA 
pharmacophore. Our experiments have shown several candidate haploid deletion 
strains that are hypersensitive to PelA that could be used for random mutagenesis by 
a chemical carcinogen like ethylmethanesulfonate (EMS). The best approach would 
be to treat the haploid deletion strain with EMS to induce random mutations in the 
tubulin genes. The surviving cells can then be grown on a plate containing PelA in 
the medium to screen for mutants that are able to grow in the presence of the 
compound (resistant mutants). Tubulin genes of resistant yeast strains can be easily 
sequenced, and if the resistance is due to the altered tubulin, further details of the 
PelA binding site would be obtained. Random mutagenesis by PCR can also be used, 
taking advantage of error-prone PCR (EP-PCR) by further decreasing the fidelity of 
Taq DNA polymerase (by adding Mn2+ and increasing the Mg2+ conc.) and using 
unequal dNTP concentrations. The level of mutagenesis can be “controlled” 
chemically and by the number of “doublings”. The disadvantage of this technique is 
that it needs a series of optimisation reactions to ensure non-specific primer 
annealing is not an issue and to determine amplification efficiency for doubling 
estimates. However, both of the above suggestions require significant amounts of 
PelA, and proceeding with these studies at this time is not possible because the PelA 
supply in our laboratory is very scarce.   
 
Other experiments that need to be carried out are in situ tubulin polymerisation and 
immunohistochemistry experiments. The in situ polymerisation would test whether 
PelA actually polymerises tubulin inside the cell. This could be coupled with PelA 
effects on purified yeast tubulin, as has been carried out for Ptx and Epo by other 
researchers (Barnes et al. 1992; Bode et al. 2002). Purification of yeast tubulin 
protein could be accomplished through the use of a novel tandem affinity purification 
(TAP) tag. In brief, this method requires that endogenous tubulin protein in the cell 
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be replaced with a tagged tubulin version. The gene can be replaced by homologous 
recombination in haploid cells (Rigaut et al. 1999). Tubulin could be TAP-tagged on 
either the C- or N- terminus of the protein. The TAP-tag is then used to pull-down 
tubulin from a yeast homogenate, following which the TAG is cleaved off, yielding 
purified tubulin. Both α- and β-tubulin would need to be purified in this way to 
support in vitro polymerisation experiments with PelA. 
 
More refined immunocytochemistry studies could be used to further confirm that 
PelA binds to and alters microtubular structure in yeast cells. The resolution of the 
Opera confocal microscope to pick up GFP-tubulin structural changes was not 
sufficient to determine if microtubule structure was altered by PelA in yeast, as it is 
in mammalian cells (i.e. bundling, multiple asters and spindles). Use of a high-
resolution confocal microscope and immunofluorescent staining of tubulin may 
provide more information on microtubule structure in the cells. 
 
Another very valuable approach that could be used to identify secondary targets of 
PelA is the use of DARTS (drug affinity responsive target stability). This is a very 
interesting new technique that was first described at the end of 2009 (Lomenick et al. 
2009) (Fig. 4.1).  
 
Figure. 4.1. Schematic view of DART. Binding of drugs is proposed to stabilise target proteins, 
either globally or locally, e.g. in a specific conformation or by simply masking protease recognition 
sites, thereby reducing protease sensitivity of the target protein (from Lomenick et al. 2009). 
 
The technique is based on the idea that binding of a drug to a protein results in a 
pronounced and specific protection of its target protein from protease digestion. This 
specificity can be exploited to identify unknown binding targets of a small molecule 
with any cell lysate or protein mixture, followed by mass spectrometry analysis to 
identify which proteins were protected by the presence of the drug from protease 
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digestion. DARTS does not require labelled ligands and instead uses ‘‘native’’ (i.e. 
unmodified) small molecules for binding, it is not limited by the chemistry of the 
molecule, and can potentially be used for any small molecule.  
 
The future of PelA in advancing into clinical trials will depend on increasing total 
synthesis of PelA to supply large amounts of the compound. This would also provide 
a valuable resource for further mapping of the binding site in yeast tubulin by 
providing sufficient amounts to carry out random mutagenesis experiments, and by 
performing DART. 
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Appendices 
Appendix I 
Media 
YPD   1L 
Yeast Extract        10 g 
Peptone         20 g 
Adenine        0.12 g 
Agar        20 g   (to YPD plates) 
After autoclaving add 50 mL of 40% glucose solution and the desired antibiotic (G418 200 µg/mL, 
CloneNat 100 µg/mL). The antibiotics were added after autoclaving and cooling of the medium to 
approximately 60 ◦C. 
   
SD Media 1L 
Yeast Nitrogen Base without amino acid    1.7 g 
MSG        1 g 
Amino Acid Mixture to suit     2 g 
Agar        20 g (to SD plates) 
 
After autoclaving add 50 mL of 40% glucose solution and the desired antibiotic (G418 200 µg/mL, 
CloneNat 100 µg/mL). The antibiotics were added after autoclaving and cooling of the medium to 
approximately 60 ◦C. 
 
1% agarose gel ( 35mL) 
agarose powder       0.35 g 
1x TBE buffer       35 mL 
 
4% MetaPhor agarose gel 
MetaPhor agarose      1.6 g  
chilled TBE buffer      40 mL 
 
Wait 15 min before heating. After polymerization store at 4ºC for at least 30 min (prior to 
electrophoresis). 
 
10x TBE (Tris borate EDTA) buffer (1 L) 
Tris (121.14 g/mol)      108 g 
boric acid (61.84 g/mol)      55 g 
EDTA (292.25 g/mol)      5.8 g 
 
Working concentration: Make 1x. Dissolve initially in 800 mL of dH2O and then adjust to pH 8 with 
HCl. Then make up volume to 1 L. 
 
LB Medium 1L 
Bacto-Tryptone        10 g  
Bacto-yeast extract       5 g  
NaCl         10 g  
Bacto-agar        15 g (to LB plates) 
 
The 100 mg/ml filter-sterilised ampicillin antibiotic was added after autoclaving and cooling of the 
medium to approximately 60 ◦C. 
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Appendix II 
 
Primer sequences for TUB2 point mutation: 
Primer A (forward) have a sequence as follow:  
tub2_A296T  
5’-TTTAGATCTTTGACTGTCCCTGAATTAACACAGCAAATGTTTGATACCAAGAACA 
TGA-3’ 
 
tub2_R306H  
5’-CAGCAAATGTTTGATGCCAAGAACATGATGGCTGCTGCCGATCCACATAACGGTA 
GAT-3’ 
 
tub2_A296T + R306H  
5’-TTTAGATCTTTGACTGTCCCTGAATTAACACAGCAAATGTTTGATACCAAGAACAT 
GATGGCTGCTGCCGATCCACATAACGGTAGAT-3’ 
 
tub2_R282Q 
5’-ATGGTCGGCTACGCTCCATTGACGGCAATTGGCTCTCAATCATTTCAATCTTTGAC 
TG-3’ 
 
tub2_Q291M 
5’-ATTGGCTCTCAATCATTTAGATCTTTGACTGTCCCTGAATTAACAATGCAAATGTT 
TG-3’ 
 
tub2_V333W 
5’-AGAGGTAAAGTTTCCGTTAAGGAGGTGGAAGATGAAATGCATAAATGGCAATCTAA 
AA-3’ 
 
tub2_N337L 
5’-TCCGTTAAGGAGGTGGAAGATGAAATGCATAAAGTGCAATCTAAACTCTCAGACTA 
TT-3’ 
 
Primer B (Reverse) 
5’-GGGTATTCTGGGCCTCCATGTCTATATTCACTAATACTCGGGGTGT-3’ 
 
 
Primer C (Forward) 
5’-ACACCCCGAGTATTAGTGAATATAGACATGGAGGCCCAGAATACCC-3’ 
 
(Blue-coloured letters designate homology to nat-resistance cassette region on the 
plasmid, and black-coloured letters are the region homolog to gDNA) 
 
Primer D (Reverse) 
5’-AAATCCCTGATCTGCGTAATATTGCAAGTTCTTTTTTATCGGCCCCAGTATAGCGAC 
CAGCATTCAC-3’ 
 
(Green colour coded letters represent homology to natMX-cassette region on the 
plasmid (as explained earlier); however, black colour letters represent homology to 
gDNA) 
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Transformation confirmation primer: 
 
Forward primer: Primer A (400 bp upstream of point mutation) 
5’-GATGGCCACCTTCTCCGT-3’ 
 
 
Reverse primers:   
 
A296T 
5’-AGCCATCATGTTCTTGGC-3’ (WT)   or      
5’-AGCCATCATGTTCTTGGT-3’ (µ) 
 
R306H 
5’-AAGGTATCTACCGTTTCT-3’ (WT)   or       
5’-AAGGTATCTACCGTTATG-3’ (µ) 
 
R282Q 
5’-AGGGACAGTCAAAGATCT-3’ (WT) or        
5’-AGGGACAGTCAAAGATTG-3’ (µ) 
 
Q291M 
5’-GGCATCAAACATTTGCTG-3’ (WT)   or        
5’-GGCATCAAACATTTGCAT-3’ (µ) 
 
V333W 
5’-TGAGTTTTTAGATTGCAC-3’ (WT)   or          
5’-TGAGTTTTTAGATTGCCA-3’ (µ) 
 
N337L 
5’-CACGAAATAGTCTGAGTT-3’ (WT) or       
5’-CACGAAATAGTCTGAGAG-3’ (µ) 
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Appendix III 
 
The NatMX cassette 
Frozen bacterial cultures containing the plasmid p4339 (see figure below) for the 
NatMX cassette were streaked on LB plates containing 100 µg/ml ampicillin and 
grown at 37°C overnight under shaking. The following day, a single colony was 
inoculated in 2 mL LB medium (Appendix I) containing 100 µg/ml ampicillin and 
grown at 37°C overnight under shaking. The plasmid purification was accomplished 
using the QIAprep® Miniprep Kit (Qiagen) according to the manufacturer’s 
protocol. The NatMX cassette was then PCR-amplified using forward primer C and 
reverse primer D refer to Materials and Methods -in chapter 2- section 2.2.2 (primer 
sequences are Appendix II)  
 
 
The figure illustrates the p4339 plasmid that encodes for NatMX antibiotic resistant marker. 
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Appendix IV 
PelA-mutant strains glycerol stock number  
 
Point mutation Glycerol Stock # Genotype 
A296T YCG248 
MAT a mad2∆::G418 tub2-A296T:: NatMX ura3∆0 
leu2∆0his3∆1 met15∆1 
R306H YCG249 
MAT a mad2∆::G418 tub2- R306H:: NatMX ura3∆0 
leu2∆0his3∆1 met15∆1 
A296T + R306H YCG243 
MAT a mad2∆::G418 tub2- A296T+R306H:: NatMX 
ura3∆0 leu2∆0his3∆1 met15∆1 
R282Q YCG257 
MAT a mad2∆::G418 tub2- R282Q:: NatMX ura3∆0 
leu2∆0his3∆1 met15∆1 
Q291M YCG258 
MAT a mad2∆::G418 tub2- Q291M:: NatMX ura3∆0 
leu2∆0his3∆1 met15∆1 
V333W YCG279 
MAT a mad2∆::G418 tub2- V333W:: NatMX ura3∆0 
leu2∆0his3∆1 met15∆1 
N337L YCG259 
MAT a mad2∆::G418 tub2- N337L:: NatMX ura3∆0 
leu2∆0his3∆1 met15∆1 
 
 
 
 
 
Yeast gene and protein nomenclature 
 
Type Description  Example 
Yeast wild type genes Capital letters, italics  MAD2 
Yeast mutant genes Small letters, italics, ∆  mad2∆ 
Yeast proteins Capitalised first letter Mad2 
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Appendix V 
Gene description obtained from SGD Stanford for HOP hit list: 
 
ORF Gene Name Description 
YBL065W - Dubious open reading frame unlikely to encode a protein. 
YBL054W TOD6 Protein involved in rRNA and ribosome biogenesis. 
YBR189W RPS9B Protein component of the small (40S) ribosomal subunit. 
YCL029C BIK1 
Microtubule-associated protein, involved in sister chromatid 
separation. 
YDL115C IWR1 Protein of unknown function. 
YDR017C KCS1 
Encodes one of two yeast inositol pyrophosphate synthases, 
required vacuolar biogenesis, the stress response, DNA repair, cell 
wall synthesis, telomere maintenance, and phosphate homeostasis. 
YDR264C AKR1 Palmitoyl transferase involved in protein palmitoylation; acts as a 
negative regulator of pheromone response pathway 
YDR441C APT2 Apparent pseudogene, not transcribed or translated under normal 
conditions. 
YER087W AIM10 Protein with similarity to tRNA synthetases; null mutant is viable 
and displays elevated frequency of mitochondrial genome loss. 
YGL086W MAD1 Coiled-coil protein involved in the spindle-assembly checkpoint, forms a complex with Mad2p. 
YGL170C SPO74 
Component of the meiotic outer plaque of the spindle pole body, 
involved in modifying the meiotic outer plaque that is required 
prior to prospore membrane formation. 
YIL157C COA1 
Mitochondrial inner membrane protein required for assembly of 
the cytochrome c oxidase complex (complex IV) 
YJL030W MAD2 Component of the spindle-assembly checkpoint complex, forms a 
complex with Mad1p. 
YJL124C LSM1 
Lsm (Like Sm) protein; forms heteroheptameric complex (with 
Lsm2p, Lsm3p, Lsm4p, Lsm5p, Lsm6p, and Lsm7p) involved in 
degradation of cytoplasmic mRNAs. (Lsm) proteins are a highly 
conserved family of ancient origin, found in bacteria, archaea, and 
eukaryotes. 
YKL212W SAC1 
Encodes a lipid phosphatase that is involved in many cellular 
processes, such as cell wall maintenance and membrane and 
protein trafficking. 
YML008C ERG6 
Converts zymosterol to fecosterol in the ergosterol biosynthetic 
pathway by methylating position C-24. Cells lacking ERG6 are 
viable but unable to methylate sterols on C-24, and exhibit 
pleiotropic growth phenotypes. 
YNL054W VAC7 Integral vacuolar membrane protein involved in vacuole inheritance and morphology. 
YNL187W SWT21 Protein of unknown function. 
YNL280C ERG24 Encodes C-14 sterol reductase, an enzyme that acts in ergosterol biosynthesis. 
YOR014W RTS1 B-type regulatory subunit of protein phosphatase 2A (homolog of the mammalian B' subunit of PP2A). 
YOR019W - Protein of unknown function. 
YOR161C PNS1 Protein of unknown function. 
YOR292C - Putative protein of unknown function. 
YPL018W CTF19 Outer kinetochore protein, required for accurate mitotic 
chromosome segregation. 
YPL187W MF(Alpha)1 Mating pheromone alpha-factor, made by alpha cells. 
 
